https://trial.medpath.com/news/lisata-therapeutics-extends-cash-runway-to-q4-2026-advances-certepetide-development-through-catalent-partnership 2025-08-08T17:38:26+00:00 hourly 0.9 https://trial.medpath.com/news/fosun-s-hlx43-cancer-drug-rights-deal-with-j-j-and-roche-could-generate-hundreds-of-millions-in-strategic-ip-monetization 2025-08-08T17:37:48+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-reports-positive-phase-iii-results-for-oral-glp-1-therapy-orforglipron-in-type-2-diabetes-and-obesity 2025-08-08T17:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/kiora-pharmaceuticals-advances-two-phase-2-retinal-disease-trials-secures-110m-asian-partnership 2025-08-08T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-therapy-shows-unprecedented-promise-as-potential-cure-for-lupus-in-early-clinical-trials 2025-08-08T17:34:47+00:00 hourly 0.9 https://trial.medpath.com/news/hope-therapeutics-receives-florida-regulatory-approval-for-dura-medical-acquisition-to-expand-precision-psychiatry-network 2025-08-08T17:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/iovance-biotherapeutics-implements-major-restructuring-amid-regulatory-setbacks-and-commercial-challenges 2025-08-08T17:33:35+00:00 hourly 0.9 https://trial.medpath.com/news/wcc-biomedical-advances-microneedle-drug-delivery-platform-with-winmap-technology-at-nacds-expo 2025-08-08T17:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/genmab-s-epkinly-achieves-79-reduction-in-disease-progression-risk-in-phase-iii-follicular-lymphoma-trial 2025-08-08T17:32:44+00:00 hourly 0.9 https://trial.medpath.com/news/capivasertib-causes-distinctive-glucose-spikes-in-breast-cancer-patient-prompting-japanese-safety-warning 2025-08-08T13:25:49+00:00 hourly 0.9 https://trial.medpath.com/news/roswell-park-researchers-develop-first-genomic-tool-to-guide-kidney-cancer-immunotherapy-decisions 2025-08-08T13:25:14+00:00 hourly 0.9 https://trial.medpath.com/news/codex-genetics-partners-with-pacific-edge-to-bring-non-invasive-bladder-cancer-testing-to-hong-kong 2025-08-08T13:23:50+00:00 hourly 0.9 https://trial.medpath.com/news/remegen-receives-fda-clearance-for-phase-ii-trial-of-bispecific-antibody-rc148-in-advanced-solid-tumors 2025-08-08T13:23:27+00:00 hourly 0.9 https://trial.medpath.com/news/orchestra-biomed-expands-backbeat-hypertension-trial-eligibility-24-fold-following-fda-protocol-approval 2025-08-08T13:23:16+00:00 hourly 0.9 https://trial.medpath.com/news/10x-genomics-acquires-scale-biosciences-to-expand-single-cell-analysis-capabilities 2025-08-08T09:37:38+00:00 hourly 0.9 https://trial.medpath.com/news/skye-bioscience-reports-promising-preclinical-data-for-nimacimab-as-obesity-treatment-ahead-of-phase-2a-results 2025-08-08T09:34:08+00:00 hourly 0.9 https://trial.medpath.com/news/trinity-biotech-launches-fda-cleared-preeclampsia-testing-service-with-potential-10-million-cost-savings 2025-08-08T09:31:13+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-secures-370-million-settlement-and-future-royalties-in-curevac-biontech-mrna-patent-dispute 2025-08-08T09:30:25+00:00 hourly 0.9 https://trial.medpath.com/news/smart-hydrogel-achieves-90-diabetic-wound-closure-in-12-days-through-novel-mirna-therapy 2025-08-08T09:29:20+00:00 hourly 0.9 https://trial.medpath.com/news/89bio-advances-phase-3-trials-for-pegozafermin-in-mash-and-severe-hypertriglyceridemia-with-561m-cash-position 2025-08-08T09:27:09+00:00 hourly 0.9 https://trial.medpath.com/news/dewpoint-therapeutics-cuts-70-of-workforce-refocuses-on-lead-cancer-drug-dptx3186 2025-08-08T09:24:16+00:00 hourly 0.9 https://trial.medpath.com/news/kura-oncology-s-ziftomenib-receives-fda-priority-review-for-npm1-mutant-aml-pdufa-date-set-for-november-2025 2025-08-08T05:37:39+00:00 hourly 0.9 https://trial.medpath.com/news/progressive-supranuclear-palsy-market-poised-for-growth-as-emerging-therapies-advance-through-clinical-trials 2025-08-08T05:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/newcastle-study-shows-safe-withdrawal-of-eculizumab-in-rare-kidney-disease-saving-nhs-ps4-2-million-per-patient 2025-08-08T05:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/retension-pharmaceuticals-secures-15m-series-b-to-advance-novel-hypertension-drug-rtn-001-into-phase-2b-trial 2025-08-08T05:33:17+00:00 hourly 0.9 https://trial.medpath.com/news/insulin-access-disparities-persist-despite-cost-stabilization-study-reveals-long-term-health-system-burden 2025-08-08T03:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/infectious-disease-screening-in-substance-use-treatment-programs-shows-dramatic-increases-in-detection-and-prevention 2025-08-08T03:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-supply-chains-face-new-challenges-from-tariffs-and-ai-disruption 2025-08-08T03:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/myriad-genetics-reports-strong-q2-2025-results-pivots-strategy-to-focus-on-cancer-care-continuum 2025-08-08T03:30:56+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-testing-reduces-severe-chemotherapy-side-effects-by-42-in-gastrointestinal-cancer-patients 2025-08-08T01:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/relay-therapeutics-advances-rly-2608-to-phase-3-trial-with-promising-breast-cancer-data 2025-08-08T01:38:21+00:00 hourly 0.9 https://trial.medpath.com/news/biomendics-launches-tames-02-trial-for-first-in-class-eb-simplex-therapy-tolasure 2025-08-08T01:36:36+00:00 hourly 0.9 https://trial.medpath.com/news/cassava-sciences-appoints-joseph-hulihan-as-chief-medical-officer-to-lead-simufilam-development-for-tsc-related-epilepsy 2025-08-08T01:34:10+00:00 hourly 0.9 https://trial.medpath.com/news/arcellx-reports-strong-car-t-clinical-data-despite-72-revenue-drop-in-q2-2025 2025-08-08T01:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-evidence-validates-bispecific-antibodies-as-effective-treatment-option-in-relapsed-refractory-multiple-myeloma 2025-08-08T01:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/pattern-computer-secures-global-patent-protection-for-ai-discovered-triple-negative-breast-cancer-therapy-pci020302 2025-08-08T01:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/ignite-proteomics-partners-with-vanderbilt-to-advance-breast-cancer-immunotherapy-biomarker-discovery 2025-08-08T01:31:03+00:00 hourly 0.9 https://trial.medpath.com/news/fibrogen-receives-fda-approval-for-phase-3-trial-of-roxadustat-in-lower-risk-mds-patients-with-high-transfusion-burden 2025-08-08T01:29:52+00:00 hourly 0.9 https://trial.medpath.com/news/iovance-reports-strong-q2-2025-results-with-60m-revenue-as-amtagvi-adoption-accelerates 2025-08-08T01:29:30+00:00 hourly 0.9 https://trial.medpath.com/news/daxor-receives-fda-clearance-for-next-generation-blood-volume-analyzer-with-3x-faster-analysis 2025-08-08T01:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/annexon-s-vonaprument-selected-for-ema-s-product-development-coordinator-pilot-program-for-dry-amd-treatment 2025-08-08T01:28:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-liquid-embolic-system-for-hypervascular-tumor-treatment 2025-08-08T01:28:22+00:00 hourly 0.9 https://trial.medpath.com/news/sequence-lifescience-receives-irb-approval-for-novel-matched-controls-trial-in-diabetic-foot-ulcers 2025-08-08T01:27:12+00:00 hourly 0.9 https://trial.medpath.com/news/triple-combination-therapy-shows-promise-for-ruxolitinib-resistant-myelofibrosis-patient 2025-08-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/viiv-healthcare-s-n6ls-broadly-neutralizing-antibody-shows-promise-in-phase-2b-hiv-trial 2025-08-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sellas-life-sciences-receives-positive-idmc-recommendation-to-continue-phase-3-regal-trial-of-galinpepimut-s-in-aml 2025-08-07T21:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-pkids-trial-challenges-standard-pediatric-kidney-stone-treatment-approaches 2025-08-07T21:41:43+00:00 hourly 0.9 https://trial.medpath.com/news/faers-database-analysis-reveals-safety-profile-of-imiglucerase-in-gaucher-disease-treatment 2025-08-07T21:39:40+00:00 hourly 0.9 https://trial.medpath.com/news/quince-therapeutics-partners-with-option-care-health-to-streamline-edsp-commercialization-for-rare-disease-treatment 2025-08-07T21:39:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-for-replimune-s-rp1-oncolytic-immunotherapy-delaying-melanoma-launch 2025-08-07T21:37:44+00:00 hourly 0.9 https://trial.medpath.com/news/strand-therapeutics-raises-153m-series-b-to-advance-programmable-mrna-cancer-therapies 2025-08-07T21:37:13+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-cachexia-pipeline-shows-promise-with-20-therapies-in-development-across-multiple-companies 2025-08-07T21:35:40+00:00 hourly 0.9 https://trial.medpath.com/news/dulaglutide-biosimilar-ly05008-demonstrates-therapeutic-equivalence-in-phase-3-trial-for-type-2-diabetes 2025-08-07T21:35:35+00:00 hourly 0.9 https://trial.medpath.com/news/cardiol-therapeutics-stock-plunges-20-as-cbd-based-cardiolrx-misses-primary-endpoints-in-myocarditis-trial 2025-08-07T21:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/avobis-bio-seeks-fda-fast-track-status-for-implantable-cell-therapy-following-positive-crohn-s-fistula-trial 2025-08-07T21:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-asthma-drug-zileuton-shows-promise-in-preventing-food-allergy-reactions 2025-08-07T21:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/sanome-s-ai-platform-memori-receives-class-iib-ce-certification-for-early-healthcare-associated-infection-detection 2025-08-07T21:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/brightwater-research-prepares-clinical-trials-for-anti-metastatic-lung-cancer-drug-valoxydin 2025-08-07T21:32:33+00:00 hourly 0.9 https://trial.medpath.com/news/nccn-updates-small-cell-lung-cancer-guidelines-to-include-lambert-eaton-myasthenic-syndrome-testing-and-treatment 2025-08-07T17:39:51+00:00 hourly 0.9 https://trial.medpath.com/news/annovis-bio-secures-comprehensive-patent-protection-for-crystal-buntanetap-through-2046 2025-08-07T17:39:47+00:00 hourly 0.9 https://trial.medpath.com/news/tegoprazan-demonstrates-superior-long-term-gerd-management-in-phase-3-triumph-study 2025-08-07T17:38:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ajovy-as-first-cgrp-antagonist-for-pediatric-migraine-prevention 2025-08-07T17:38:44+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-rules-optional-storage-instructions-don-t-induce-patent-infringement-in-generic-drug-case 2025-08-07T17:38:08+00:00 hourly 0.9 https://trial.medpath.com/news/iovance-biotherapeutics-cuts-workforce-by-nearly-20-following-slow-amtagvi-cell-therapy-launch 2025-08-07T17:37:51+00:00 hourly 0.9 https://trial.medpath.com/news/maxona-pharmaceuticals-submits-ind-application-for-max-001-novel-non-opioid-pain-treatment 2025-08-07T17:37:41+00:00 hourly 0.9 https://trial.medpath.com/news/nice-recommends-first-nhs-treatment-for-rare-eye-disease-lhon-ending-access-disparity-in-england 2025-08-07T17:37:15+00:00 hourly 0.9 https://trial.medpath.com/news/alexion-secures-canadian-access-agreement-for-ultomiris-in-two-rare-autoimmune-diseases 2025-08-07T17:37:11+00:00 hourly 0.9 https://trial.medpath.com/news/intas-pharmaceuticals-and-accord-biopharma-acquire-udenyca-biosimilar-expanding-global-pegfilgrastim-market-presence 2025-08-07T17:36:35+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-study-confirms-tamiflu-safety-in-children-debunks-neuropsychiatric-risk-concerns 2025-08-07T17:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/apreo-health-raises-130-million-to-advance-pivotal-trial-for-novel-emphysema-device 2025-08-07T17:34:37+00:00 hourly 0.9 https://trial.medpath.com/news/ph-responsive-graphene-nanomaterials-achieve-enhanced-tumor-targeting-in-breakthrough-cancer-drug-delivery-study 2025-08-07T17:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/mass-general-brigham-launches-clinical-trials-for-haystack-mrd-ctdna-test-in-head-and-neck-and-skin-cancers 2025-08-07T17:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/meta-analysis-confirms-epimedium-s-efficacy-in-primary-osteoporosis-treatment 2025-08-07T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/faron-pharmaceuticals-reports-43-complete-remission-rate-in-high-risk-myelodysplastic-syndrome-trial 2025-08-07T13:29:17+00:00 hourly 0.9 https://trial.medpath.com/news/minghui-pharmaceutical-secures-131-million-pre-ipo-funding-to-advance-oncology-pipeline-and-commercial-launch 2025-08-07T13:29:06+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-gene-therapy-ga001-shows-promise-in-restoring-vision-for-retinitis-pigmentosa-patients 2025-08-07T13:28:13+00:00 hourly 0.9 https://trial.medpath.com/news/regenxbio-advances-gene-therapy-to-pivotal-phase-iib-iii-trial-for-diabetic-retinopathy 2025-08-07T13:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/valneva-overcomes-fda-safety-pause-for-ixchiq-chikungunya-vaccine-strengthens-market-position 2025-08-07T13:27:29+00:00 hourly 0.9 https://trial.medpath.com/news/sinomed-s-cometiu-stent-system-faces-regulatory-setback-in-china-despite-fda-breakthrough-designation 2025-08-07T13:27:17+00:00 hourly 0.9 https://trial.medpath.com/news/fujifilm-and-horiba-develop-revolutionary-gene-delivery-system-with-100x-productivity-boost-for-gene-therapy-manufacturing 2025-08-07T09:25:58+00:00 hourly 0.9 https://trial.medpath.com/news/almirall-and-absci-expand-ai-drug-discovery-partnership-with-second-dermatology-target 2025-08-07T09:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/expert-highlights-optimal-positioning-of-bispecific-t-cell-engagers-in-multiple-myeloma-treatment 2025-08-07T09:24:50+00:00 hourly 0.9 https://trial.medpath.com/news/modular-medical-completes-clinical-study-of-modd1-insulin-pump-prepares-for-next-generation-pivot-launch 2025-08-07T09:14:17+00:00 hourly 0.9 https://trial.medpath.com/news/cartherics-opens-advanced-cell-therapy-manufacturing-facility-to-support-cth-401-clinical-development 2025-08-07T05:28:51+00:00 hourly 0.9 https://trial.medpath.com/news/voyager-therapeutics-advances-single-dose-aav-gene-therapy-vy-1706-for-alzheimer-s-disease-targeting-ind-filing-in-2026 2025-08-07T05:28:49+00:00 hourly 0.9 https://trial.medpath.com/news/blood-based-protein-analysis-achieves-85-8-accuracy-in-predicting-triple-negative-breast-cancer-immunotherapy-response 2025-08-07T01:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/day-one-biopharmaceuticals-reports-310-revenue-surge-for-pediatric-cancer-drug-ojemda 2025-08-07T01:32:41+00:00 hourly 0.9 https://trial.medpath.com/news/precision-biosciences-reports-first-clinical-evidence-of-hepatitis-b-gene-editing-therapy-pbgene-hbv 2025-08-07T01:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/lonza-excellos-and-akadeum-form-strategic-alliance-to-transform-cell-therapy-manufacturing-quality 2025-08-07T01:29:49+00:00 hourly 0.9 https://trial.medpath.com/news/protagonist-therapeutics-files-first-nda-for-icotrokinra-in-psoriasis-advances-rusfertide-for-polycythemia-vera 2025-08-07T01:29:19+00:00 hourly 0.9 https://trial.medpath.com/news/chai-discovery-raises-70m-series-a-to-revolutionize-antibody-design-with-ai-platform-achieving-20-hit-rate 2025-08-07T01:29:12+00:00 hourly 0.9 https://trial.medpath.com/news/phase-ii-trial-shows-nestacell-r-dental-pulp-stem-cell-therapy-significantly-improves-motor-function-in-huntington-s-disease-patients 2025-08-07T01:29:05+00:00 hourly 0.9 https://trial.medpath.com/news/henlius-initiates-phase-2-trial-of-first-in-class-sialidase-therapy-hlx79-combined-with-rituximab-for-glomerulonephritis 2025-08-07T01:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/ftc-blocks-edwards-lifesciences-945m-jenavalve-acquisition-over-tavr-ar-device-competition-concerns 2025-08-07T01:27:52+00:00 hourly 0.9 https://trial.medpath.com/news/novel-nanoparticle-therapy-agg-clnp-shows-promise-for-preventing-rheumatoid-arthritis-and-reducing-flares 2025-08-06T21:37:37+00:00 hourly 0.9 https://trial.medpath.com/news/cardurion-completes-enrollment-in-phase-2-trials-for-novel-heart-failure-drug-crd-750 2025-08-06T21:37:27+00:00 hourly 0.9 https://trial.medpath.com/news/renovorx-reports-strong-q2-2025-commercial-growth-and-positive-phase-iii-trial-continuation 2025-08-06T21:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/therabene-appoints-dr-oscar-kashala-as-cmo-to-advance-protein-degrader-pipeline-for-hard-to-treat-cancers 2025-08-06T21:35:49+00:00 hourly 0.9 https://trial.medpath.com/news/phase-i-trial-establishes-maximum-tolerated-dose-for-pegylated-liposomal-doxorubicin-plus-ifosfamide-in-advanced-soft-tissue-sarcoma 2025-08-06T21:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-advances-coramitug-to-phase-3-for-attr-cardiomyopathy-following-successful-phase-2-trial 2025-08-06T21:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/dual-clinical-trials-advance-mesothelioma-treatment-with-novel-immunotherapy-combinations 2025-08-06T21:33:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-first-accelerated-approval-for-h3-k27m-mutated-diffuse-midline-glioma-with-dordaviprone 2025-08-06T21:31:54+00:00 hourly 0.9 https://trial.medpath.com/news/harvard-study-reveals-lithium-deficiency-as-potential-driver-of-alzheimer-s-disease 2025-08-06T17:46:07+00:00 hourly 0.9 https://trial.medpath.com/news/astria-therapeutics-secures-16-million-japan-partnership-for-hereditary-angioedema-treatment-navenibart 2025-08-06T17:41:54+00:00 hourly 0.9 https://trial.medpath.com/news/mark-cuban-s-cost-plus-drugs-expands-pharmacy-network-through-giant-eagle-partnership 2025-08-06T17:41:52+00:00 hourly 0.9 https://trial.medpath.com/news/percheron-s-hmbd-002-shows-promise-against-triple-negative-breast-cancer-in-preclinical-studies 2025-08-06T17:40:51+00:00 hourly 0.9 https://trial.medpath.com/news/polyactiva-initiates-us-phase-2b-trial-for-six-month-biodegradable-glaucoma-implant-pa5108 2025-08-06T17:40:21+00:00 hourly 0.9 https://trial.medpath.com/news/insmed-reports-strong-q2-2025-results-with-arikayce-growth-and-brensocatib-approval-pending 2025-08-06T17:39:52+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-dendritic-cell-therapy-shows-promise-for-glioblastoma-in-phase-1-trial 2025-08-06T17:39:49+00:00 hourly 0.9 https://trial.medpath.com/news/diamedica-therapeutics-appoints-julie-krop-as-chief-medical-officer-to-advance-dm199-development 2025-08-06T17:39:13+00:00 hourly 0.9 https://trial.medpath.com/news/standard-biotools-somascan-platform-selected-for-singapore-s-landmark-100000-sample-precision-medicine-study 2025-08-06T17:38:18+00:00 hourly 0.9 https://trial.medpath.com/news/samson-clinical-initiates-phase-iii-trial-of-sublingual-minoxidil-for-male-pattern-hair-loss 2025-08-06T17:38:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-birelentinib-for-relapsed-refractory-cll-sll 2025-08-06T17:37:22+00:00 hourly 0.9 https://trial.medpath.com/news/revvity-launches-phsense-reagents-to-accelerate-gpcr-and-adc-drug-development 2025-08-06T17:35:59+00:00 hourly 0.9 https://trial.medpath.com/news/dana-farber-boston-children-s-hospital-and-broad-clinical-labs-launch-brightseq-initiative-for-pediatric-cancer-genomics 2025-08-06T17:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-tocilizumab-anoh-biosimilar-for-cytokine-release-syndrome-treatment 2025-08-06T17:34:58+00:00 hourly 0.9 https://trial.medpath.com/news/oxaliplatin-shows-survival-benefit-only-in-stage-iii-colorectal-cancer-patients-under-70-years 2025-08-06T15:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/jama-surgery-study-validates-dex-g2-blood-test-for-early-gastric-cancer-detection-with-95-sensitivity 2025-08-06T13:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/lantheus-secures-fda-acceptance-for-enhanced-psma-pet-imaging-agent-with-50-increased-batch-size 2025-08-06T13:26:33+00:00 hourly 0.9 https://trial.medpath.com/news/mannkind-secures-500-million-strategic-financing-from-blackstone-to-advance-inhaled-therapeutics-pipeline 2025-08-06T13:25:38+00:00 hourly 0.9 https://trial.medpath.com/news/novel-nmda-receptor-modulator-onfasprodil-shows-rapid-antidepressant-effects-with-reduced-side-effects-in-phase-2-trial 2025-08-06T13:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/two-versus-three-cycles-of-induction-chemotherapy-show-similar-survival-outcomes-in-advanced-nasopharyngeal-carcinoma 2025-08-06T13:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/two-major-trials-show-egfr-inhibitors-fail-to-improve-outcomes-in-head-and-neck-cancer 2025-08-06T13:25:14+00:00 hourly 0.9 https://trial.medpath.com/news/cognitive-functional-therapy-shows-sustained-benefits-for-chronic-low-back-pain-after-three-years 2025-08-06T13:24:28+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-establishes-clinical-trial-platform-in-victoria-to-accelerate-cancer-treatment-access 2025-08-06T13:24:05+00:00 hourly 0.9 https://trial.medpath.com/news/immunoprecise-antibodies-divests-netherlands-operations-for-12m-to-focus-on-ai-driven-drug-discovery-platform 2025-08-06T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-regulation-of-cues-therapy-shows-20-greater-efficacy-than-standard-treatment-for-binge-eating-disorder-in-veterans 2025-08-06T09:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/galapagos-receives-fda-rmat-designation-for-car-t-therapy-glpg5101-in-relapsed-refractory-mantle-cell-lymphoma 2025-08-06T09:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/ainnova-tech-revises-clinical-trial-protocol-for-ai-based-diabetic-retinopathy-detection-following-fda-feedback 2025-08-06T09:28:10+00:00 hourly 0.9 https://trial.medpath.com/news/new-zealand-s-fast-track-approvals-act-faces-early-implementation-challenges-as-rejection-rates-rise 2025-08-06T09:28:01+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-medical-technology-companies-launch-clinical-trials-for-revolutionary-ct-imaging-systems-in-shanghai 2025-08-06T09:27:51+00:00 hourly 0.9 https://trial.medpath.com/news/membrane-tethered-slp-76-engineering-overcomes-car-t-cell-limitations-against-low-antigen-tumors 2025-08-06T05:22:53+00:00 hourly 0.9 https://trial.medpath.com/news/bracco-imaging-receives-nmpa-approval-for-sonovue-in-female-infertility-assessment-in-china 2025-08-06T05:22:09+00:00 hourly 0.9 https://trial.medpath.com/news/esmo-2025-delivers-breakthrough-bladder-cancer-results-with-perioperative-immunotherapy-combinations 2025-08-06T05:22:04+00:00 hourly 0.9 https://trial.medpath.com/news/nxera-pharma-launches-comprehensive-obesity-pipeline-with-novel-oral-glp-1-agonist 2025-08-06T05:21:07+00:00 hourly 0.9 https://trial.medpath.com/news/bluerock-therapeutics-advances-bemdaneprocel-to-phase-iii-for-parkinson-s-disease-as-market-projected-to-reach-7-0-billion-by-2033 2025-08-06T03:00:18+00:00 hourly 0.9 https://trial.medpath.com/news/high-discontinuation-rates-plague-pediatric-clinical-trials-as-researchers-push-for-child-centric-design 2025-08-06T02:59:04+00:00 hourly 0.9 https://trial.medpath.com/news/casi-pharmaceuticals-surges-57-following-fda-clearance-for-cid-103-kidney-transplant-rejection-therapy 2025-08-06T01:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/idmc-recommends-continuation-of-eli-002-7p-phase-2-trial-in-pancreatic-cancer-following-positive-interim-analysis 2025-08-06T01:28:44+00:00 hourly 0.9 https://trial.medpath.com/news/hmnc-brain-health-s-bh-200-shows-promising-results-in-phase-2-depression-trial-with-genetic-selection-tool 2025-08-06T01:28:16+00:00 hourly 0.9 https://trial.medpath.com/news/nalu-medical-s-comfort-2-trial-establishes-first-level-1-evidence-for-permanent-peripheral-nerve-stimulation-in-chronic-pain 2025-08-06T01:28:14+00:00 hourly 0.9 https://trial.medpath.com/news/forcast-orthopedics-secures-series-a-funding-to-advance-novel-periprosthetic-joint-infection-therapies 2025-08-06T01:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-adopts-intact-nmr-spectroscopy-for-enhanced-quality-assessment-of-nanoemulsion-drug-formulations 2025-08-06T01:27:33+00:00 hourly 0.9 https://trial.medpath.com/news/democratic-senators-challenge-fda-s-approval-of-juul-e-cigarettes-amid-conflict-of-interest-concerns 2025-08-06T01:26:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-cgrp-antagonist-for-pediatric-migraine-prevention-as-ajovy-expands-to-children 2025-08-06T01:26:12+00:00 hourly 0.9 https://trial.medpath.com/news/aurobindo-pharma-acquires-lannett-for-250m-to-expand-us-adhd-therapeutics-portfolio 2025-08-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cho-plus-secures-10-4m-barda-contract-to-develop-cell-lines-for-filovirus-monoclonal-antibody-production 2025-08-05T21:28:15+00:00 hourly 0.9 https://trial.medpath.com/news/promega-secures-patent-victory-against-aobious-in-luciferase-technology-dispute 2025-08-05T21:26:33+00:00 hourly 0.9 https://trial.medpath.com/news/ategenos-secures-foundational-patent-for-smartpatch-platform-addressing-1t-medication-non-adherence-crisis 2025-08-05T21:26:31+00:00 hourly 0.9 https://trial.medpath.com/news/flare-therapeutics-initiates-phase-1b-trial-of-first-in-class-pparg-inhibitor-fx-909-for-advanced-urothelial-cancer 2025-08-05T21:25:56+00:00 hourly 0.9 https://trial.medpath.com/news/kashiv-biosciences-partners-with-ms-pharma-for-mena-launch-of-omalizumab-biosimilar-adl-018 2025-08-05T21:25:14+00:00 hourly 0.9 https://trial.medpath.com/news/civicascript-announces-low-cost-ustekinumab-biosimilar-distribution-to-expand-access-to-inflammatory-disease-treatment 2025-08-05T21:25:12+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-discontinues-praluent-supply-to-china-amid-global-demand-surge-and-local-competition 2025-08-05T21:25:10+00:00 hourly 0.9 https://trial.medpath.com/news/akyso-therapeutics-advances-long-acting-opioid-use-disorder-treatment-with-successful-phase-1a-trial-and-15m-nih-grant 2025-08-05T21:24:46+00:00 hourly 0.9 https://trial.medpath.com/news/vitiligo-treatment-pipeline-shows-promise-with-jak-inhibitors-and-novel-immunotherapies-in-phase-3-trials 2025-08-05T21:23:57+00:00 hourly 0.9 https://trial.medpath.com/news/porosome-therapeutics-reports-breakthrough-alzheimer-s-platform-with-fda-validated-organoid-studies-and-ai-designed-therapeutics 2025-08-05T21:23:49+00:00 hourly 0.9 https://trial.medpath.com/news/imperial-college-s-react-study-partners-with-dementia-trials-accelerator-to-transform-clinical-trial-recruitment 2025-08-05T21:23:08+00:00 hourly 0.9 https://trial.medpath.com/news/biomark-diagnostics-doubles-laboratory-capacity-to-accelerate-lung-cancer-assay-commercialization 2025-08-05T17:54:45+00:00 hourly 0.9 https://trial.medpath.com/news/merck-s-ifinatamab-deruxtecan-receives-fda-breakthrough-designation-for-small-cell-lung-cancer 2025-08-05T17:50:53+00:00 hourly 0.9 https://trial.medpath.com/news/epicrispr-biotechnologies-doses-first-patient-with-epi-321-novel-epigenetic-therapy-for-facioscapulohumeral-muscular-dystrophy 2025-08-05T17:50:05+00:00 hourly 0.9 https://trial.medpath.com/news/ac-immune-reports-strong-immunogenicity-data-for-parkinson-s-disease-vaccine-in-phase-2-trial 2025-08-05T17:45:35+00:00 hourly 0.9 https://trial.medpath.com/news/synox-therapeutics-completes-enrollment-in-phase-3-trial-of-emactuzumab-for-rare-joint-tumor 2025-08-05T17:45:30+00:00 hourly 0.9 https://trial.medpath.com/news/kyoto-university-develops-non-addictive-painkiller-adriana-as-morphine-alternative 2025-08-05T17:45:09+00:00 hourly 0.9 https://trial.medpath.com/news/corbus-pharmaceuticals-receives-fda-fast-track-designation-for-investigational-therapy 2025-08-05T17:44:36+00:00 hourly 0.9 https://trial.medpath.com/news/novel-bacterial-consortium-aun-achieves-tumor-eradication-without-immune-system-dependence 2025-08-05T17:44:28+00:00 hourly 0.9 https://trial.medpath.com/news/shattuck-labs-secures-103-million-to-advance-first-in-class-dr3-antibody-sl-325-through-phase-2-trials 2025-08-05T17:43:14+00:00 hourly 0.9 https://trial.medpath.com/news/serb-pharmaceuticals-to-acquire-y-mabs-therapeutics-for-412-million-expanding-rare-oncology-portfolio 2025-08-05T17:42:47+00:00 hourly 0.9 https://trial.medpath.com/news/ripk1-inhibitor-pipeline-shows-promise-despite-sanofi-setback-in-multiple-sclerosis 2025-08-05T17:42:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-provides-positive-feedback-on-immutep-s-eftilagimod-alfa-for-head-and-neck-cancer-treatment 2025-08-05T17:42:07+00:00 hourly 0.9 https://trial.medpath.com/news/gensight-s-gene-therapy-shows-better-outcomes-when-administered-during-dynamic-phase-of-lhon-disease 2025-08-05T17:41:48+00:00 hourly 0.9 https://trial.medpath.com/news/sophia-genetics-and-astrazeneca-expand-ai-partnership-to-optimize-breast-cancer-treatment-outcomes 2025-08-05T17:41:20+00:00 hourly 0.9 https://trial.medpath.com/news/yatiri-bio-acquires-ngenebioai-to-strengthen-ai-powered-proteomics-platform-for-precision-medicine 2025-08-05T17:38:49+00:00 hourly 0.9 https://trial.medpath.com/news/gut-metabolite-imidazole-propionate-identified-as-novel-atherosclerosis-driver-and-therapeutic-target 2025-08-05T17:38:47+00:00 hourly 0.9 https://trial.medpath.com/news/israeli-researchers-achieve-first-long-term-growth-of-human-kidney-organoids-opening-path-to-regenerative-therapies 2025-08-05T17:38:44+00:00 hourly 0.9 https://trial.medpath.com/news/contract-manufacturing-industry-report-reveals-impact-of-global-conflicts-and-inflation-on-pharmaceutical-production 2025-08-05T17:38:29+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-generic-drug-approval-delays-threaten-patient-access-and-healthcare-cost-savings 2025-08-05T17:37:41+00:00 hourly 0.9 https://trial.medpath.com/news/nih-launches-escape-trial-to-test-maternal-diet-s-role-in-preventing-early-food-allergies-in-infants 2025-08-05T17:37:31+00:00 hourly 0.9 https://trial.medpath.com/news/gedeon-richter-reintroduces-dydrogesterone-only-hrt-option-to-uk-market-after-17-year-absence 2025-08-05T17:36:38+00:00 hourly 0.9 https://trial.medpath.com/news/mdxhealth-acquires-bio-techne-s-exodx-prostate-test-platform-in-15-million-strategic-deal 2025-08-05T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/global-study-reveals-chronic-spontaneous-urticaria-patients-face-greater-disease-burden-than-other-inflammatory-skin-conditions 2025-08-05T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/180-life-sciences-pivots-from-biotech-to-ethereum-treasury-strategy-with-581-million-in-funding 2025-08-05T13:36:02+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-sets-ambitious-900m-935m-voxzogo-revenue-target-for-2025-amid-strategic-portfolio-restructuring 2025-08-05T13:35:33+00:00 hourly 0.9 https://trial.medpath.com/news/axogen-raises-2025-revenue-growth-target-to-17-as-avance-nerve-graft-bla-approval-approaches 2025-08-05T13:35:21+00:00 hourly 0.9 https://trial.medpath.com/news/sensei-biotherapeutics-advances-vista-targeting-cancer-therapy-with-q2-2025-results-and-esmo-presentation 2025-08-05T13:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/polpharma-biologics-and-fresenius-kabi-partner-on-vedolizumab-biosimilar-for-inflammatory-bowel-disease 2025-08-05T13:31:06+00:00 hourly 0.9 https://trial.medpath.com/news/mcl-1-inhibitors-advance-toward-clinical-breakthrough-with-over-12-drugs-in-development-pipeline 2025-08-05T13:29:30+00:00 hourly 0.9 https://trial.medpath.com/news/ethris-initiates-phase-2a-trial-of-novel-mrna-therapy-eth47-for-viral-triggered-asthma-exacerbations 2025-08-05T13:29:25+00:00 hourly 0.9 https://trial.medpath.com/news/nucleus-network-acquires-hammersmith-medicines-research-to-create-global-early-phase-clinical-trial-network 2025-08-05T13:28:51+00:00 hourly 0.9 https://trial.medpath.com/news/fapon-biopharma-enrolls-first-patient-in-phase-i-trial-of-fp008-novel-anti-pd-1-fusion-protein-for-solid-tumors 2025-08-05T13:28:49+00:00 hourly 0.9 https://trial.medpath.com/news/intranasal-stem-cell-therapy-shows-promise-for-newborn-brain-injury-in-passion-safety-trial 2025-08-05T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/korean-biotech-hyundai-bioscience-reports-positive-phase-ii-results-for-oral-covid-19-treatment-cp-cov03 2025-08-05T10:58:54+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-plans-generic-semaglutide-launch-in-canada-with-up-to-70-price-reduction 2025-08-05T09:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/taconic-and-cyagen-form-strategic-partnership-to-expand-access-to-16000-genetically-engineered-mouse-models 2025-08-05T09:30:54+00:00 hourly 0.9 https://trial.medpath.com/news/tempest-therapeutics-advances-phase-3-trial-of-tpst-1120-combination-for-hepatocellular-carcinoma 2025-08-05T09:28:42+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-dyanavel-xr-extended-release-amphetamine-for-adhd-treatment-in-adults-and-children 2025-08-05T08:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/metis-technologies-raises-rmb-400-million-series-d-to-advance-ai-driven-nanodelivery-platform 2025-08-05T05:30:04+00:00 hourly 0.9 https://trial.medpath.com/news/cyclacel-s-plogosertib-shows-promise-against-biliary-tract-cancer-in-preclinical-study 2025-08-05T05:29:54+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-confirms-safety-and-efficacy-of-trastuzumab-biosimilar-ct-p6-in-her2-positive-gastric-cancer 2025-08-05T05:29:41+00:00 hourly 0.9 https://trial.medpath.com/news/sarilumab-demonstrates-significant-quality-of-life-improvements-in-polymyalgia-rheumatica-phase-3-trial 2025-08-05T05:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/syndax-reports-strong-q2-2025-results-with-revuforj-revenue-growth-and-pending-fda-approval-for-npm1-aml 2025-08-05T01:33:06+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-study-reveals-hidden-cancer-cells-in-42-of-ovarian-cancer-patients-in-clinical-remission 2025-08-05T01:27:40+00:00 hourly 0.9 https://trial.medpath.com/news/grifols-alzheimer-vaccine-abvac40-demonstrates-53-reduction-in-cognitive-decline-risk-in-phase-2-trial 2025-08-05T01:27:31+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-pharmaceuticals-discontinues-vx-993-development-after-phase-2-failure-in-acute-pain 2025-08-05T01:27:07+00:00 hourly 0.9 https://trial.medpath.com/news/first-commercial-brain-gene-therapy-treatments-delivered-in-us-using-clearpoint-neuro-s-smartflow-cannula 2025-08-05T01:26:58+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-confirms-safety-and-efficacy-of-aflibercept-biosimilar-pavblu-in-6313-patients 2025-08-05T01:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/redwire-launches-spacemd-to-commercialize-space-grown-pharmaceutical-crystals 2025-08-05T01:25:20+00:00 hourly 0.9 https://trial.medpath.com/news/sonelokimab-shows-promising-24-week-results-in-phase-2-psoriatic-arthritis-trial 2025-08-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-human-hiv-vaccine-trial-begins-in-africa-using-novel-gorilla-adenovirus-vector-platform 2025-08-04T21:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/tg-therapeutics-reports-91-revenue-surge-driven-by-briumvi-multiple-sclerosis-treatment 2025-08-04T21:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/agios-pharmaceuticals-addresses-safety-concerns-as-pyrukynd-receives-saudi-approval-for-thalassemia 2025-08-04T21:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/tearcare-system-demonstrates-cost-savings-and-superior-outcomes-compared-to-cyclosporine-in-dry-eye-treatment 2025-08-04T21:30:56+00:00 hourly 0.9 https://trial.medpath.com/news/rapid-dose-therapeutics-submits-quickstrip-nicotine-oral-film-for-health-canada-approval 2025-08-04T21:30:51+00:00 hourly 0.9 https://trial.medpath.com/news/car-macrophages-generated-in-situ-via-mrna-loaded-extracellular-vesicles-show-promise-against-lung-metastasis 2025-08-04T21:30:24+00:00 hourly 0.9 https://trial.medpath.com/news/combination-therapy-achieves-15-month-progression-free-survival-in-advanced-large-cell-neuroendocrine-lung-carcinoma 2025-08-04T21:30:11+00:00 hourly 0.9 https://trial.medpath.com/news/xoma-acquires-struggling-biotechs-hillevax-and-lava-therapeutics-in-strategic-consolidation-move 2025-08-04T21:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/agios-pharmaceuticals-faces-fda-delay-for-pyrukynd-thalassemia-approval-amid-safety-concerns 2025-08-04T21:28:20+00:00 hourly 0.9 https://trial.medpath.com/news/bmi-organbank-receives-fda-breakthrough-device-designation-for-room-temperature-kidney-preservation-technology 2025-08-04T21:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-receives-fda-clearance-for-first-tags-powered-respiratory-test-detecting-four-major-viruses 2025-08-04T21:26:56+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-bath-develops-oral-delivery-system-for-injectable-protein-drugs 2025-08-04T21:26:51+00:00 hourly 0.9 https://trial.medpath.com/news/praxis-precision-medicines-reports-56-seizure-reduction-with-vormatrigine-despite-stock-decline 2025-08-04T21:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/tg-therapeutics-initiates-phase-3-trial-for-subcutaneous-briumvi-in-multiple-sclerosis 2025-08-04T17:42:08+00:00 hourly 0.9 https://trial.medpath.com/news/tharimmune-advances-th104-as-national-security-solution-against-weaponized-fentanyl-secures-5-47m-funding 2025-08-04T17:38:17+00:00 hourly 0.9 https://trial.medpath.com/news/onemednet-expands-real-world-data-network-by-25-adding-5-billion-administrative-records 2025-08-04T17:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/sonnet-biotherapeutics-expands-son-1010-trial-after-promising-response-rate-in-platinum-resistant-ovarian-cancer 2025-08-04T17:35:56+00:00 hourly 0.9 https://trial.medpath.com/news/pulsecare-medical-s-nxpfatm-receives-nmpa-approval-as-world-s-first-nanosecond-pulsed-field-ablation-system 2025-08-04T17:35:21+00:00 hourly 0.9 https://trial.medpath.com/news/freya-pharma-launches-phase-ii-study-of-lybrido-for-female-sexual-dysfunction-using-novel-blood-flow-measurement 2025-08-04T17:34:53+00:00 hourly 0.9 https://trial.medpath.com/news/transmedics-receives-fda-approval-for-largest-heart-transplant-preservation-trial 2025-08-04T17:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-s-inkmune-therapy-meets-primary-endpoints-in-phase-1-2-prostate-cancer-trial 2025-08-04T17:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/davion-healthcare-files-for-nasdaq-direct-listing-to-advance-non-invasive-medical-technologies 2025-08-04T17:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/medicus-pharma-and-helixnano-partner-to-develop-needle-free-heat-stable-mrna-vaccines 2025-08-04T13:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/australian-researchers-identify-nod2-gene-variants-as-key-to-enhanced-cancer-immunotherapy-response 2025-08-04T13:04:59+00:00 hourly 0.9 https://trial.medpath.com/news/atavistik-bio-doses-first-patient-in-phase-1-trial-of-atv-1601-for-akt1-e17k-mutant-solid-tumors 2025-08-04T13:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/guy-s-and-st-thomas-nhs-trust-expands-advanced-therapy-manufacturing-capacity-by-60-to-meet-growing-cell-and-gene-therapy-demand 2025-08-04T13:04:38+00:00 hourly 0.9 https://trial.medpath.com/news/tildrakizumab-demonstrates-sustained-efficacy-and-safety-in-elderly-psoriasis-patients-over-two-years 2025-08-04T13:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/chocolate-compound-theobromine-combined-with-arainosine-outperforms-tamiflu-against-drug-resistant-flu-strains 2025-08-04T13:03:18+00:00 hourly 0.9 https://trial.medpath.com/news/microbiotica-completes-enrollment-in-phase-1b-trial-of-mb310-for-ulcerative-colitis 2025-08-04T13:02:07+00:00 hourly 0.9 https://trial.medpath.com/news/neuroendocrine-tumor-pipeline-shows-strong-growth-with-75-therapies-in-development 2025-08-04T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/certara-s-simcyp-simulator-becomes-first-pbpk-modeling-platform-to-receive-ema-qualification-for-eu-regulatory-submissions 2025-08-04T09:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/phnyx-lab-secures-4m-to-advance-ai-powered-medical-writing-platform-for-life-sciences 2025-08-04T09:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/raytone-biotech-doses-first-patient-with-novel-tacrolimus-plug-for-dry-eye-disease 2025-08-04T09:26:49+00:00 hourly 0.9 https://trial.medpath.com/news/anbogen-receives-fda-clearance-for-phase-1-2-trial-of-abt-301-triplet-therapy-in-metastatic-colorectal-cancer 2025-08-04T09:26:47+00:00 hourly 0.9 https://trial.medpath.com/news/alveolus-bio-secures-strategic-investment-from-shilpa-medicare-to-advance-respiratory-therapeutics-platform 2025-08-04T05:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/alphamab-oncology-receives-ind-approval-for-first-in-class-bispecific-adc-jskn022-targeting-pd-l1-and-integrin-avb6 2025-08-04T05:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-michigan-develops-at-home-melanoma-detection-patch-using-microneedle-technology 2025-08-04T05:05:25+00:00 hourly 0.9 https://trial.medpath.com/news/green-space-exposure-during-pregnancy-and-early-childhood-reduces-risk-of-neurodevelopmental-disorders 2025-08-04T05:00:13+00:00 hourly 0.9 https://trial.medpath.com/news/dep-sn38-dendrimer-nanoparticle-shows-promise-in-advanced-solid-tumors-with-reduced-toxicity-profile 2025-08-04T01:27:59+00:00 hourly 0.9 https://trial.medpath.com/news/australia-develops-world-first-mrna-vaccine-for-foot-and-mouth-disease-in-livestock 2025-08-03T22:03:20+00:00 hourly 0.9 https://trial.medpath.com/news/united-imaging-launches-fda-cleared-umr-ultra-3t-mri-system-with-dynamic-motion-visualization-technology 2025-08-03T22:00:36+00:00 hourly 0.9 https://trial.medpath.com/news/indian-regulators-scrutinize-biodeal-s-midazolam-nasal-spray-pricing-exemption-amid-nlem-inclusion-controversy 2025-08-03T14:10:05+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-human-study-of-mrna-2416-shows-promise-in-advanced-solid-tumors-and-ovarian-cancer 2025-08-03T14:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/luye-pharma-initiates-phase-1-trial-for-novel-triple-target-antidepressant-ly03021 2025-08-03T14:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-panel-recommends-approval-for-vorasidenib-with-phase-iii-waiver-for-idh-mutant-gliomas-in-india 2025-08-03T09:57:15+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-requests-protocol-revisions-for-novartis-itu512-sickle-cell-disease-trial 2025-08-03T09:57:11+00:00 hourly 0.9 https://trial.medpath.com/news/lg-group-invests-in-strand-therapeutics-mrna-cancer-platform-through-series-b-funding 2025-08-03T06:03:14+00:00 hourly 0.9 https://trial.medpath.com/news/new-peritoneal-surface-malignancy-guidelines-address-critical-care-gaps-for-70000-us-patients-annually 2025-08-03T03:24:16+00:00 hourly 0.9 https://trial.medpath.com/news/ice-t-conference-highlights-critical-need-for-standardized-car-t-cell-therapy-supportive-care-protocols 2025-08-03T03:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/indian-clinical-trial-shows-one-third-of-type-2-diabetes-patients-achieve-drug-free-remission 2025-08-03T01:40:28+00:00 hourly 0.9 https://trial.medpath.com/news/aptinyx-prepares-for-fda-meeting-on-novel-ptsd-treatment-nyx-783 2025-08-03T01:39:11+00:00 hourly 0.9 https://trial.medpath.com/news/greek-led-clinical-trial-shows-40-reduction-in-death-risk-for-small-cell-lung-cancer-patients 2025-08-02T22:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-semaglutide-launch-in-canada-faces-regulatory-delay-following-compliance-notice 2025-08-02T18:10:58+00:00 hourly 0.9 https://trial.medpath.com/news/blacksmith-medicines-advances-novel-antibiotic-fg-2101-targeting-drug-resistant-gram-negative-bacteria 2025-08-02T18:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/archimed-acquires-ai-powered-antimicrobial-stewardship-company-arkstone-medical-group 2025-08-02T18:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/novel-car-nk-cell-therapy-and-chemotherapy-combinations-show-promise-for-pediatric-and-relapsed-aml-treatment 2025-08-02T18:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/teodor-trial-launches-to-test-personalized-neoadjuvant-therapy-for-early-stage-breast-cancer 2025-08-02T18:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/myriad-genetics-secures-200-million-credit-facility-from-orbimed-to-fuel-growth-strategy 2025-08-02T14:11:24+00:00 hourly 0.9 https://trial.medpath.com/news/novel-nanoparticle-formulations-enhance-paclitaxel-delivery-to-cancer-tumors 2025-08-02T14:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/phase-2-skyline-trial-shows-promising-results-for-gene-therapy-in-x-linked-retinitis-pigmentosa 2025-08-02T14:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/sava-technologies-achieves-10-day-continuous-glucose-monitoring-milestone-with-next-generation-microsensor-platform 2025-08-02T14:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-syfovre-data-shows-early-treatment-benefits-and-sustained-safety-in-geographic-atrophy 2025-08-02T10:11:24+00:00 hourly 0.9 https://trial.medpath.com/news/federal-court-strikes-down-fda-s-narrow-interpretation-of-orphan-drug-exclusivity-in-neurelis-v-brenner 2025-08-02T05:19:30+00:00 hourly 0.9 https://trial.medpath.com/news/systematic-review-reveals-significant-disparities-in-us-biologics-access-across-immunology-specialties 2025-08-02T03:24:37+00:00 hourly 0.9 https://trial.medpath.com/news/washington-research-foundation-awards-5-2m-to-launch-collaborative-clinical-trials-program-for-rare-cancer-therapeutics 2025-08-02T02:20:56+00:00 hourly 0.9 https://trial.medpath.com/news/purgo-scientific-appoints-james-bowman-as-ceo-to-advance-novel-drug-delivery-platform 2025-08-02T02:15:36+00:00 hourly 0.9 https://trial.medpath.com/news/hansa-biopharma-s-imlifidase-enables-gene-therapy-access-for-duchenne-patients-with-pre-existing-antibodies 2025-08-02T02:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/terbium-161-radioimmunotherapy-shows-superior-efficacy-against-ovarian-cancer-stem-cells-in-preclinical-study 2025-08-01T22:29:41+00:00 hourly 0.9 https://trial.medpath.com/news/allan-camaisa-joins-res-nova-biologics-advisory-board-to-advance-breast-cancer-immunotherapy 2025-08-01T22:19:23+00:00 hourly 0.9 https://trial.medpath.com/news/sucralose-artificial-sweetener-reduces-cancer-immunotherapy-effectiveness-through-gut-microbiome-disruption 2025-08-01T22:19:09+00:00 hourly 0.9 https://trial.medpath.com/news/spine-biopharma-s-sb-01-fails-to-meet-primary-endpoint-in-phase-3-trial-for-chronic-low-back-pain 2025-08-01T22:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-second-rejection-for-regeneron-s-lymphoma-therapy-odronextamab-due-to-manufacturing-issues 2025-08-01T22:16:42+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-reports-41-revenue-decline-in-q2-2025-launches-1-5-billion-cost-cutting-initiative 2025-08-01T17:22:41+00:00 hourly 0.9 https://trial.medpath.com/news/ozempic-shows-anti-aging-effects-in-first-clinical-trial-reversing-biological-age-by-3-1-years 2025-08-01T17:22:31+00:00 hourly 0.9 https://trial.medpath.com/news/allogene-therapeutics-modifies-alpha3-trial-design-following-patient-death-adopts-standard-lymphodepletion-protocol 2025-08-01T17:22:21+00:00 hourly 0.9 https://trial.medpath.com/news/novel-antibody-capture-system-enhances-targeted-mrna-delivery-with-8-fold-improved-binding-efficiency 2025-08-01T17:22:17+00:00 hourly 0.9 https://trial.medpath.com/news/everest-medicines-invests-30-9m-in-i-mab-following-promising-83-response-rate-for-gastric-cancer-bispecific-antibody 2025-08-01T17:21:24+00:00 hourly 0.9 https://trial.medpath.com/news/i-mab-raises-65-million-to-advance-givastomig-phase-2-trial-for-gastric-cancer 2025-08-01T17:19:02+00:00 hourly 0.9 https://trial.medpath.com/news/mabwell-s-cdh17-targeting-adc-7mw4911-receives-dual-ind-acceptance-from-fda-and-nmpa 2025-08-01T17:18:54+00:00 hourly 0.9 https://trial.medpath.com/news/esteve-cdmo-acquires-chicago-based-regis-technologies-to-expand-us-manufacturing-capabilities 2025-08-01T17:16:19+00:00 hourly 0.9 https://trial.medpath.com/news/kazia-therapeutics-secures-2-million-private-placement-to-advance-brain-cancer-and-breast-cancer-drug-development 2025-08-01T17:16:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-sets-2026-user-fee-rates-for-generic-and-animal-drug-programs-with-inflation-adjustments 2025-08-01T14:13:40+00:00 hourly 0.9 https://trial.medpath.com/news/fda-mandates-comprehensive-safety-label-changes-for-all-opioid-pain-medications 2025-08-01T14:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-engages-trump-administration-in-drug-pricing-negotiations-following-strong-q2-performance 2025-08-01T14:10:04+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-acquires-rights-to-plozasiran-for-395-million-in-greater-china-deal-with-arrowhead 2025-08-01T14:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-for-x-scid-reveals-critical-role-of-virtual-memory-t-cells-in-early-human-immunity 2025-08-01T14:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/large-real-world-study-questions-effectiveness-of-immunoglobulin-replacement-therapy-in-cll-patients 2025-08-01T09:50:17+00:00 hourly 0.9 https://trial.medpath.com/news/dpiit-and-roche-india-sign-strategic-partnership-to-accelerate-healthcare-innovation-in-critical-therapeutic-areas 2025-08-01T09:49:51+00:00 hourly 0.9 https://trial.medpath.com/news/bd-advances-at-home-hpv-testing-with-ivdr-certification-and-fda-submission-for-cervical-cancer-screening 2025-08-01T05:30:32+00:00 hourly 0.9 https://trial.medpath.com/news/knight-therapeutics-submits-minjuvi-supplemental-application-for-follicular-lymphoma-in-brazil 2025-08-01T05:30:30+00:00 hourly 0.9 https://trial.medpath.com/news/certara-appoints-ai-pioneer-dr-chris-bouton-as-cto-to-advance-next-generation-drug-development-platform 2025-08-01T05:28:06+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-victoria-and-monash-university-invest-2-25m-in-three-medical-startups-targeting-rare-disease-and-autoimmune-conditions 2025-08-01T05:27:57+00:00 hourly 0.9 https://trial.medpath.com/news/zenara-pharma-secures-first-generic-sertraline-capsule-approval-with-180-day-market-exclusivity 2025-08-01T05:27:55+00:00 hourly 0.9 https://trial.medpath.com/news/chatgpt-reduces-clinical-trial-screening-time-from-40-minutes-to-under-3-minutes-but-human-oversight-still-required 2025-08-01T05:27:48+00:00 hourly 0.9 https://trial.medpath.com/news/preventive-cardiology-experts-call-for-enhanced-cardiovascular-risk-assessment-and-early-intervention-strategies 2025-08-01T05:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/breast-cancer-treatment-de-escalation-advances-through-multi-institutional-clinical-trials 2025-08-01T05:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/health-system-fragmentation-creates-barriers-to-timely-lung-cancer-biomarker-testing 2025-08-01T03:00:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-vostally-oral-solution-first-liquid-ramipril-formulation-for-hypertension-treatment 2025-08-01T01:40:30+00:00 hourly 0.9 https://trial.medpath.com/news/maxcyte-partners-with-anocca-to-advance-tcr-t-cell-therapy-manufacturing-using-non-viral-gene-editing-platform 2025-08-01T01:39:36+00:00 hourly 0.9 https://trial.medpath.com/news/danish-study-confirms-safety-of-jn-1-updated-covid-19-mrna-vaccines-in-real-world-analysis 2025-08-01T01:34:10+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-therapy-reactivates-developmental-gene-to-repair-heart-damage-after-heart-attack 2025-08-01T01:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/radius-pharmaceuticals-secures-patent-victory-for-tymlos-osteoporosis-treatment-through-2038 2025-08-01T01:33:37+00:00 hourly 0.9 https://trial.medpath.com/news/genvira-and-labskin-secure-ps1-2-million-uk-canada-grant-for-melanoma-immunotherapy-development 2025-08-01T01:33:35+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-scientists-achieve-first-in-human-reprogramming-of-stem-cells-to-generate-renewable-cancer-fighting-t-cells 2025-08-01T01:33:28+00:00 hourly 0.9 https://trial.medpath.com/news/immunophotonics-completes-phase-1b-2a-trial-of-ip-001-immunotherapy-for-advanced-solid-tumors 2025-08-01T01:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/mitochondria-targeting-drugs-emerge-as-next-generation-obesity-treatments-to-address-glp-1-limitations 2025-08-01T01:30:59+00:00 hourly 0.9 https://trial.medpath.com/news/serina-therapeutics-advances-once-weekly-injectable-vmat2-inhibitor-for-tardive-dyskinesia-treatment 2025-08-01T01:30:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-leqvio-as-first-line-monotherapy-for-cholesterol-management 2025-08-01T01:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/vir-biotechnology-reports-positive-early-results-from-dual-masked-t-cell-engagers-trials 2025-08-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ich-opens-public-consultation-on-draft-q3e-guideline-for-extractables-and-leachables-in-drug-products 2025-08-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/benralizumab-shows-promise-in-rare-eosinophilic-disorders-beyond-asthma-study-finds 2025-08-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/biocryst-names-charlie-gayer-as-new-ceo-following-jon-stonehouse-s-retirement-announcement 2025-07-31T21:43:32+00:00 hourly 0.9 https://trial.medpath.com/news/immunitas-therapeutics-unveils-promising-preclinical-data-for-first-in-class-anti-cd161-antibody-imt-380-in-autoimmune-diseases 2025-07-31T21:41:26+00:00 hourly 0.9 https://trial.medpath.com/news/duo-trial-reveals-promise-for-durvalumab-olaparib-combination-in-early-stage-endometrial-cancer 2025-07-31T21:35:27+00:00 hourly 0.9 https://trial.medpath.com/news/phase-2-alzheimer-s-trial-reveals-significant-racial-disparities-in-patient-screening-for-tau-targeting-therapy 2025-07-31T21:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/frazier-healthcare-partners-closes-1-3-billion-fund-for-early-stage-biotech-investments 2025-07-31T21:34:15+00:00 hourly 0.9 https://trial.medpath.com/news/altasciences-partners-with-voxcell-bioinnovation-to-integrate-3d-bioprinting-technology-into-preclinical-drug-development 2025-07-31T21:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/oncodesign-precision-medicine-advances-opm-101-melanoma-trial-amid-financial-restructuring 2025-07-31T21:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/protopia-ai-secures-1-25m-air-force-contract-to-advance-privacy-preserving-ai-technology-for-secure-code-development 2025-07-31T21:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/moonlake-immunotherapeutics-advances-sonelokimab-through-phase-3-trials-for-multiple-inflammatory-conditions 2025-07-31T21:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-colorado-launches-29-million-effect-trial-to-evaluate-early-fibrinogen-replacement-in-trauma-care 2025-07-31T21:30:22+00:00 hourly 0.9 https://trial.medpath.com/news/lantern-pharma-completes-japanese-enrollment-for-phase-2-harmonic-trial-testing-lp-300-in-never-smoker-lung-cancer-patients 2025-07-31T17:40:24+00:00 hourly 0.9 https://trial.medpath.com/news/immuneonco-s-cd47xcd20-bispecific-imm0306-advances-to-phase-ii-with-promising-efficacy-in-b-cell-lymphomas 2025-07-31T17:36:21+00:00 hourly 0.9 https://trial.medpath.com/news/marengo-therapeutics-strengthens-leadership-with-pfizer-veteran-dolsten-and-oncology-expert-tabernero 2025-07-31T17:34:33+00:00 hourly 0.9 https://trial.medpath.com/news/medicenna-secures-five-new-patents-for-il-2-and-il-4-superkine-immunotherapies 2025-07-31T17:34:31+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-announces-10-workforce-reduction-as-part-of-1-5-billion-cost-cutting-initiative 2025-07-31T17:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/chipscreen-biosciences-receives-fda-ind-approval-for-brain-penetrant-aurora-b-inhibitor-cs231295 2025-07-31T17:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/vanda-pharmaceuticals-reports-strong-q2-2025-results-with-multiple-drug-applications-under-fda-review 2025-07-31T17:30:44+00:00 hourly 0.9 https://trial.medpath.com/news/symbiosis-pharmaceutical-services-achieves-manufacturing-milestone-with-1000th-sterile-injectable-batch 2025-07-31T17:29:50+00:00 hourly 0.9 https://trial.medpath.com/news/ryvu-therapeutics-discovers-synergistic-mtor-akt-inhibitor-combination-for-colorectal-cancer-treatment 2025-07-31T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-rinvoq-achieves-breakthrough-results-in-alopecia-areata-phase-iii-trial 2025-07-31T17:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-expanded-biktarvy-indication-for-hiv-treatment-experienced-patients-restarting-therapy 2025-07-31T17:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/psyence-biomed-partner-psylabs-achieves-gmp-grade-ibogaine-production-milestone 2025-07-31T17:26:11+00:00 hourly 0.9 https://trial.medpath.com/news/china-establishes-initial-pricing-mechanism-for-new-drugs-to-boost-innovation-returns 2025-07-31T17:24:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-neuroimmune-modulation-device-for-rheumatoid-arthritis-treatment 2025-07-31T17:24:06+00:00 hourly 0.9 https://trial.medpath.com/news/uk-cdmo-eramol-advances-sterile-manufacturing-facility-for-2026-launch 2025-07-31T17:23:59+00:00 hourly 0.9 https://trial.medpath.com/news/soligenix-s-sgx945-matches-efficacy-of-fda-approved-therapy-in-behcet-s-disease-phase-2a-trial 2025-07-31T17:23:37+00:00 hourly 0.9 https://trial.medpath.com/news/tirzepatide-demonstrates-cardiovascular-benefits-in-type-2-diabetes-patients-with-ascvd-and-osa 2025-07-31T14:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/ultromics-secures-55m-series-c-to-scale-ai-powered-heart-failure-diagnostics-across-us-hospitals 2025-07-31T14:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-rejects-zydus-phase-iii-clinical-trial-waiver-for-voclosporin-in-lupus-nephritis-treatment 2025-07-31T13:49:53+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-pharmaceuticals-faces-setbacks-in-pain-medicine-development-program 2025-07-31T13:34:34+00:00 hourly 0.9 https://trial.medpath.com/news/new-market-report-reveals-global-mycosis-fungoides-clinical-trial-landscape-with-major-pharma-players 2025-07-31T13:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/aerorx-therapeutics-reports-positive-phase-2a-results-for-first-nebulized-laba-lama-combination-therapy-aero-007-in-copd 2025-07-31T13:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharmaceutical-companies-lead-global-renal-failure-clinical-trials-landscape-in-2025 2025-07-31T13:31:13+00:00 hourly 0.9 https://trial.medpath.com/news/fresenius-medical-care-partners-with-azenta-to-advance-precision-kidney-disease-care-through-genomic-analysis 2025-07-31T13:30:25+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-first-vaccine-adjuvant-library-launches-to-accelerate-pandemic-preparedness 2025-07-31T13:30:23+00:00 hourly 0.9 https://trial.medpath.com/news/beone-medicines-receives-ema-prime-designation-for-btk-degrader-bgb-16673-in-waldenstrom-s-macroglobulinemia 2025-07-31T13:29:21+00:00 hourly 0.9 https://trial.medpath.com/news/flu-associated-brain-swelling-in-children-shows-27-mortality-rate-despite-aggressive-treatment 2025-07-31T10:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/unlv-researchers-achieve-99-pancreas-specific-mrna-delivery-using-novel-endo-nanoparticle-platform 2025-07-31T09:26:55+00:00 hourly 0.9 https://trial.medpath.com/news/touchlight-launches-mbdna-platform-achieving-75-knock-in-rates-in-primary-human-t-cells 2025-07-31T05:24:08+00:00 hourly 0.9 https://trial.medpath.com/news/lung-cancer-experts-convene-to-address-clinical-uncertainties-in-rapidly-evolving-treatment-landscape 2025-07-31T03:00:21+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-safety-management-strategies-transform-pi3k-inhibitor-treatment-delivery-in-metastatic-breast-cancer 2025-07-31T02:58:18+00:00 hourly 0.9 https://trial.medpath.com/news/kidney-cancer-experts-develop-new-strategies-to-advance-clinical-trials-for-rare-subtypes 2025-07-31T02:58:16+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-launches-patent-challenge-against-chinese-military-institute-over-remdesivir-at-unified-patent-court 2025-07-31T01:01:18+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-in-advanced-talks-to-acquire-mental-health-company-gilgamesh-pharmaceuticals-for-1-billion 2025-07-31T00:59:58+00:00 hourly 0.9 https://trial.medpath.com/news/osteosarcoma-market-poised-for-significant-growth-through-2034-as-novel-therapies-enter-pipeline 2025-07-31T00:59:55+00:00 hourly 0.9 https://trial.medpath.com/news/inka-health-partners-with-onemednet-to-develop-ai-powered-external-control-arms-for-cancer-drug-development 2025-07-31T00:58:36+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-modeyso-as-first-treatment-for-recurrent-h3-k27m-mutant-diffuse-midline-glioma 2025-07-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/medicinova-secures-30-million-standby-equity-agreement-to-advance-neurological-and-fibrotic-disease-programs 2025-07-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/topcon-acquires-ai-powered-diabetic-retinopathy-screening-company-iris-to-expand-connected-care-platform 2025-07-30T21:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/sensei-biotherapeutics-to-present-phase-1-data-on-novel-vista-targeting-cancer-therapy-at-esmo-2025 2025-07-30T21:34:19+00:00 hourly 0.9 https://trial.medpath.com/news/teva-raises-uzedy-revenue-outlook-to-190-200m-as-medincell-s-olanzapine-injectable-advances-toward-fda-filing 2025-07-30T21:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-loses-patent-term-extension-battle-for-venclexta-cancer-drug-against-uspto 2025-07-30T21:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-settles-denosumab-biosimilar-patent-dispute-with-accord-biopharma 2025-07-30T21:30:09+00:00 hourly 0.9 https://trial.medpath.com/news/alcon-unveils-next-generation-retinal-surgery-technologies-at-asrs-annual-meeting 2025-07-30T21:29:53+00:00 hourly 0.9 https://trial.medpath.com/news/ai-driven-drug-repurposing-identifies-four-fda-approved-medications-with-lipid-lowering-effects 2025-07-30T21:29:38+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-and-revna-biosciences-launch-targeted-egfr-therapy-for-lung-cancer-patients-in-ghana 2025-07-30T21:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-celiac-drug-shows-promise-in-treating-children-with-post-covid-inflammatory-syndrome 2025-07-30T21:27:17+00:00 hourly 0.9 https://trial.medpath.com/news/briapro-files-patent-for-tilsrx-platform-targeting-multiple-cancer-types-with-novel-multivalent-immunotherapy 2025-07-30T17:45:44+00:00 hourly 0.9 https://trial.medpath.com/news/eumentis-therapeutics-receives-fda-clearance-for-phase-2-trial-of-novel-pde10a-inhibitor-em-221-in-schizophrenia 2025-07-30T17:43:57+00:00 hourly 0.9 https://trial.medpath.com/news/actio-biosciences-receives-fda-clearance-and-fast-track-designation-for-first-in-class-kcnt1-epilepsy-treatment 2025-07-30T17:43:31+00:00 hourly 0.9 https://trial.medpath.com/news/german-federal-patent-court-revokes-key-xarelto-patent-opening-door-for-generic-competition 2025-07-30T17:43:10+00:00 hourly 0.9 https://trial.medpath.com/news/aldevron-establishes-innovation-center-in-boston-biotech-hub-to-accelerate-genomic-medicine-development 2025-07-30T17:41:58+00:00 hourly 0.9 https://trial.medpath.com/news/protagenic-therapeutics-secures-japanese-patent-for-modified-stilbenoid-epilepsy-treatment-through-2041 2025-07-30T17:41:53+00:00 hourly 0.9 https://trial.medpath.com/news/zuma-7-trial-demonstrates-survival-advantage-for-second-line-car-t-therapy-in-refractory-dlbcl 2025-07-30T17:41:21+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-immunotherapies-linked-to-increased-risk-of-liver-cholestasis-global-study-reveals 2025-07-30T17:41:05+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-tim-3-inhibitor-cobolimab-fails-phase-iii-trial-in-advanced-lung-cancer 2025-07-30T17:40:09+00:00 hourly 0.9 https://trial.medpath.com/news/vyne-therapeutics-repibresib-gel-fails-to-meet-primary-endpoints-in-phase-2b-vitiligo-trial 2025-07-30T17:39:58+00:00 hourly 0.9 https://trial.medpath.com/news/magentiq-eye-secures-series-a-funding-to-advance-ai-powered-colonoscopy-technology 2025-07-30T17:38:45+00:00 hourly 0.9 https://trial.medpath.com/news/world-first-gene-therapy-restores-vision-in-patient-with-usher-syndrome-type-1b 2025-07-30T17:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/nautilus-biotechnology-partners-with-allen-institute-to-advance-alzheimer-s-research-through-single-molecule-proteomics 2025-07-30T17:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/ionis-pharmaceuticals-reports-strong-q2-2025-results-raises-guidance-on-tryngolza-success 2025-07-30T17:34:34+00:00 hourly 0.9 https://trial.medpath.com/news/cardiosense-receives-fda-clearance-for-cardiotag-first-wearable-to-monitor-heart-rhythm-and-mechanical-function 2025-07-30T17:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/emerald-clinical-trials-appoints-glenn-kerkhof-as-interim-ceo-following-leadership-transition 2025-07-30T17:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-vt3989-for-mesothelioma-treatment 2025-07-30T17:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/bioduro-and-atombeat-launch-ai-powered-platform-to-accelerate-peptide-drug-discovery 2025-07-30T17:33:19+00:00 hourly 0.9 https://trial.medpath.com/news/prisma-health-and-siemens-healthineers-expand-50m-partnership-to-advance-ai-driven-cancer-care 2025-07-30T13:36:44+00:00 hourly 0.9 https://trial.medpath.com/news/dx-vx-secures-220-million-mrna-cancer-vaccine-licensing-deal-with-u-s-biotech-partner 2025-07-30T13:30:27+00:00 hourly 0.9 https://trial.medpath.com/news/briacell-secures-new-zealand-patent-for-hla-matched-whole-cell-cancer-immunotherapy-technology 2025-07-30T13:30:25+00:00 hourly 0.9 https://trial.medpath.com/news/anika-s-hyalofast-cartilage-repair-treatment-shows-mixed-results-in-phase-iii-trial 2025-07-30T13:29:57+00:00 hourly 0.9 https://trial.medpath.com/news/avacta-to-present-updated-phase-1a-data-for-fap-targeted-doxorubicin-conjugate-ava6000-at-esmo-2025 2025-07-30T13:29:49+00:00 hourly 0.9 https://trial.medpath.com/news/viridian-therapeutics-secures-385-million-deal-with-kissei-for-thyroid-eye-disease-therapies-in-japan 2025-07-30T13:29:21+00:00 hourly 0.9 https://trial.medpath.com/news/evotec-sells-toulouse-biologics-facility-to-sandoz-for-300m-in-strategic-asset-light-transition 2025-07-30T13:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-analysis-launches-ga-map-mhi-guthealth-diagnostic-kit-for-recurrent-c-difficile-infection 2025-07-30T13:27:36+00:00 hourly 0.9 https://trial.medpath.com/news/bioventus-secures-fda-clearance-for-two-next-generation-peripheral-nerve-stimulation-devices 2025-07-30T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharma-companies-establish-innovation-hubs-in-hyderabad-to-accelerate-drug-development 2025-07-30T09:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/nuoyuan-medical-s-pemefolacianine-completes-phase-i-trial-advances-precision-tumor-surgery 2025-07-30T09:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/italy-approves-first-gene-therapy-for-hemophilia-b-expanding-access-to-22-new-treatments 2025-07-30T09:27:47+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-sar446523-receives-fda-orphan-drug-designation-for-relapsed-refractory-multiple-myeloma 2025-07-30T09:27:41+00:00 hourly 0.9 https://trial.medpath.com/news/mission-barns-secures-first-usda-approval-for-cultivated-pork-fat-launches-commercial-products 2025-07-30T09:27:20+00:00 hourly 0.9 https://trial.medpath.com/news/esc-congress-2025-to-showcase-pivotal-cardiovascular-trials-with-global-health-impact 2025-07-30T09:27:18+00:00 hourly 0.9 https://trial.medpath.com/news/china-launches-major-trial-testing-nafamostat-mesilate-for-sepsis-treatment-across-32-hospitals 2025-07-30T09:27:16+00:00 hourly 0.9 https://trial.medpath.com/news/esmo-2025-to-showcase-breakthrough-immunotherapy-trials-in-head-and-neck-and-endocrine-cancers 2025-07-30T09:27:09+00:00 hourly 0.9 https://trial.medpath.com/news/bd-receives-fda-510-k-clearance-for-rapid-point-of-care-covid-19-test 2025-07-30T06:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/harbour-biomed-to-present-phase-ii-data-on-novel-anti-ctla-4-antibody-combination-for-treatment-resistant-colorectal-cancer-at-esmo-2025 2025-07-30T05:24:42+00:00 hourly 0.9 https://trial.medpath.com/news/md-anderson-partners-with-toppan-holdings-to-develop-organoid-based-personalized-cancer-treatment-platform 2025-07-30T05:24:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-official-dr-vinay-prasad-resigns-after-three-months-amid-sarepta-gene-therapy-controversy 2025-07-30T05:24:32+00:00 hourly 0.9 https://trial.medpath.com/news/ivonescimab-shows-promise-as-dual-vegf-pd-1-inhibitor-in-clear-cell-renal-cell-carcinoma 2025-07-30T05:24:23+00:00 hourly 0.9 https://trial.medpath.com/news/cellipont-bioservices-expands-partnership-with-cellvax-for-personalized-gi-cancer-immunotherapy-manufacturing 2025-07-30T01:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/leo-cancer-care-s-marie-r-receives-fda-510-k-clearance-for-revolutionary-upright-particle-therapy-platform 2025-07-30T01:30:25+00:00 hourly 0.9 https://trial.medpath.com/news/kyowa-kirin-to-present-phase-3-rocatinlimab-results-for-atopic-dermatitis-at-eadv-2025 2025-07-30T01:29:59+00:00 hourly 0.9 https://trial.medpath.com/news/blood-based-assay-detects-immunotherapy-response-up-to-5-months-earlier-than-standard-imaging 2025-07-30T01:27:57+00:00 hourly 0.9 https://trial.medpath.com/news/3d-printed-catheters-enable-direct-tumor-drug-delivery-for-liver-cancer-treatment 2025-07-30T01:27:53+00:00 hourly 0.9 https://trial.medpath.com/news/diorasis-therapeutics-partners-with-northway-biotech-to-advance-aav-gene-therapy-for-open-angle-glaucoma 2025-07-30T01:27:17+00:00 hourly 0.9 https://trial.medpath.com/news/sharp-therapeutics-advances-gaucher-disease-therapy-901-toward-clinical-trials-with-rho-partnership 2025-07-30T01:26:53+00:00 hourly 0.9 https://trial.medpath.com/news/nota-ai-receives-fast-track-kosdaq-approval-for-ai-optimization-technology-ipo 2025-07-30T01:26:04+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-coagadex-for-rare-bleeding-disorder-associated-with-al-amyloidosis 2025-07-30T01:25:52+00:00 hourly 0.9 https://trial.medpath.com/news/bionexus-gene-lab-and-fidelion-diagnostics-form-strategic-alliance-to-commercialize-revolutionary-liquid-biopsy-technology-in-southeast-asia 2025-07-30T01:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/mitochondrial-transplantation-doubles-cisplatin-efficacy-in-advanced-lung-cancer-treatment 2025-07-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nice-recommends-vanzacaftor-tezacaftor-deutivacaftor-for-cystic-fibrosis-treatment-in-england 2025-07-29T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/adc-safety-management-in-mtnbc-genetic-screening-and-prophylactic-strategies-emerge-for-sacituzumab-govitecan 2025-07-29T21:36:17+00:00 hourly 0.9 https://trial.medpath.com/news/ascellahealth-and-abeona-therapeutics-launch-comprehensive-support-program-for-zevaskyn-gene-therapy 2025-07-29T21:35:25+00:00 hourly 0.9 https://trial.medpath.com/news/ltz-therapeutics-partners-with-eli-lilly-to-advance-first-in-class-myeloid-engager-platform 2025-07-29T21:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-alters-bone-marrow-environment-in-acute-myeloid-leukemia-study-reveals 2025-07-29T21:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/tme-pharma-implements-strategic-restructuring-to-advance-nox-a12-and-nox-e36-development 2025-07-29T21:30:47+00:00 hourly 0.9 https://trial.medpath.com/news/ccr-researchers-develop-water-stable-chemical-warhead-to-enhance-cancer-drug-performance 2025-07-29T21:30:41+00:00 hourly 0.9 https://trial.medpath.com/news/therini-bio-initiates-phase-1b-trial-of-novel-anti-fibrin-antibody-thn391-for-alzheimer-s-disease 2025-07-29T21:30:21+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-advances-long-term-extension-study-of-gsk1070806-for-moderate-to-severe-atopic-dermatitis 2025-07-29T21:29:58+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-shows-comparable-effectiveness-of-four-monoclonal-antibodies-in-severe-asthma-treatment 2025-07-29T21:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/formation-bio-licenses-first-in-class-anti-cd226-monoclonal-antibody-for-autoimmune-diseases 2025-07-29T21:28:44+00:00 hourly 0.9 https://trial.medpath.com/news/ema-reviews-tecovirimat-following-clinical-trial-data-showing-lack-of-effectiveness-against-mpox 2025-07-29T21:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-establishes-new-regulatory-framework-for-uvc-disinfection-systems-in-healthcare 2025-07-29T21:27:30+00:00 hourly 0.9 https://trial.medpath.com/news/bavarian-nordic-agrees-to-3-billion-take-private-deal-with-nordic-capital-and-permira 2025-07-29T21:27:15+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-investment-downturn-creates-new-opportunities-as-select-vc-firms-raise-major-funds 2025-07-29T21:27:09+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-edited-cish-knockout-til-therapy-shows-promise-in-metastatic-gastrointestinal-cancers 2025-07-29T21:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/maryland-drug-affordability-board-flags-two-diabetes-medications-as-cost-challenges 2025-07-29T17:37:09+00:00 hourly 0.9 https://trial.medpath.com/news/basilea-launches-phase-3-trial-for-novel-antifungal-fosmanogepix-in-invasive-mold-infections 2025-07-29T17:36:26+00:00 hourly 0.9 https://trial.medpath.com/news/rintatolimod-durvalumab-combination-shows-promise-in-metastatic-pancreatic-cancer-phase-2-trial 2025-07-29T17:36:19+00:00 hourly 0.9 https://trial.medpath.com/news/exonate-advances-exn407-eye-drop-to-phase-iib-trial-for-diabetic-retinopathy-treatment 2025-07-29T17:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/fulcrum-therapeutics-experimental-pill-shows-modest-increases-in-fetal-hemoglobin-for-sickle-cell-disease-treatment 2025-07-29T17:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/artbio-raises-132-million-series-b-to-advance-lead-212-radiopharmaceutical-for-prostate-cancer 2025-07-29T17:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/relief-therapeutics-to-merge-with-neurox-in-chf-1-billion-deal-creating-ai-driven-neurotherapeutics-platform 2025-07-29T17:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/ajax-therapeutics-and-schrodinger-expand-jak-inhibitor-partnership-with-new-target 2025-07-29T17:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/brain-inspired-supercomputer-deployed-at-leipzig-university-to-accelerate-ai-driven-drug-discovery 2025-07-29T17:30:47+00:00 hourly 0.9 https://trial.medpath.com/news/ai-driven-drug-design-platform-achieves-70-success-rate-in-rorgt-inhibitor-discovery 2025-07-29T17:29:57+00:00 hourly 0.9 https://trial.medpath.com/news/exozymes-achieves-breakthrough-in-nct-production-with-ai-driven-biomanufacturing-platform 2025-07-29T17:29:12+00:00 hourly 0.9 https://trial.medpath.com/news/virocell-biologics-partners-with-avencell-therapeutics-to-advance-dual-targeted-allogeneic-car-t-therapy 2025-07-29T17:28:46+00:00 hourly 0.9 https://trial.medpath.com/news/bausch-health-acquires-durect-for-63m-to-advance-breakthrough-alcoholic-hepatitis-treatment 2025-07-29T17:28:44+00:00 hourly 0.9 https://trial.medpath.com/news/centauri-therapeutics-secures-additional-5-1m-from-carb-x-to-advance-novel-antimicrobial-abx-01-to-clinical-trials 2025-07-29T17:27:26+00:00 hourly 0.9 https://trial.medpath.com/news/merck-announces-3-billion-cost-cutting-initiative-to-prepare-for-keytruda-patent-expiration 2025-07-29T17:26:40+00:00 hourly 0.9 https://trial.medpath.com/news/multibeam-raises-31-million-series-b-to-advance-e-beam-lithography-for-ai-chip-manufacturing 2025-07-29T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-receives-100-million-milestone-payment-for-aro-dm1-myotonic-dystrophy-treatment 2025-07-29T09:27:10+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-secures-preferred-bidder-status-for-us-manufacturing-facility-to-navigate-tariff-challenges 2025-07-29T09:26:17+00:00 hourly 0.9 https://trial.medpath.com/news/td2-oncology-and-curadh-form-strategic-partnership-to-accelerate-radiopharmaceutical-development-for-solid-tumors 2025-07-29T08:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/syntara-initiates-first-in-human-trial-of-topical-anti-fibrotic-drug-snt-9465-for-hypertrophic-scars 2025-07-29T05:27:34+00:00 hourly 0.9 https://trial.medpath.com/news/alphamab-oncology-s-her2-targeting-adc-jskn003-receives-fda-orphan-drug-designation-for-gastric-cancer 2025-07-29T05:26:47+00:00 hourly 0.9 https://trial.medpath.com/news/brazilian-research-institute-hcor-accelerates-phase-3-immunology-trials-with-oracle-clinical-platform 2025-07-29T05:25:57+00:00 hourly 0.9 https://trial.medpath.com/news/virax-biolabs-strengthens-board-with-diagnostics-veteran-iain-miller-as-company-advances-immune-profiling-platform 2025-07-29T04:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/fertility-preservation-gains-momentum-in-cancer-care-as-awareness-and-access-improve 2025-07-29T02:59:25+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-advances-in-sarcoma-treatment-targeting-the-tumor-microenvironment-and-cancer-testis-antigens 2025-07-29T02:58:02+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-deep-brain-stimulation-shows-promise-for-improving-walking-in-parkinson-s-disease 2025-07-29T01:29:12+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-and-bain-capital-launch-300m-immunology-drug-development-venture 2025-07-29T01:26:51+00:00 hourly 0.9 https://trial.medpath.com/news/immvira-s-engineered-exosomes-for-hair-growth-and-fat-reduction-receive-inci-certification-opening-path-to-global-markets 2025-07-29T01:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/nyxoah-s-genio-system-shows-strong-patient-satisfaction-and-efficacy-in-dream-pivotal-study-publication 2025-07-29T01:26:40+00:00 hourly 0.9 https://trial.medpath.com/news/torrent-pharmaceuticals-prepares-first-wave-semaglutide-launch-following-patent-expiry 2025-07-29T01:26:38+00:00 hourly 0.9 https://trial.medpath.com/news/adaptimmune-sells-tecelra-and-cell-therapy-assets-to-us-worldmeds-for-85-million-amid-financial-crisis 2025-07-29T01:26:29+00:00 hourly 0.9 https://trial.medpath.com/news/life-biosciences-partners-with-singapore-institute-to-advance-epigenetic-therapies-for-age-related-diseases 2025-07-29T01:25:20+00:00 hourly 0.9 https://trial.medpath.com/news/verabind-tau-assay-shows-superior-early-detection-capabilities-for-alzheimer-s-disease-in-aaic-2025-studies 2025-07-29T01:25:07+00:00 hourly 0.9 https://trial.medpath.com/news/xvivo-heart-preservation-technology-faces-6-12-month-ce-approval-delay-despite-promising-clinical-results 2025-07-29T01:23:48+00:00 hourly 0.9 https://trial.medpath.com/news/asahi-kasei-to-build-fourth-planova-virus-filter-plant-in-japan-with-government-support 2025-07-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gen-pharmaceuticals-reports-positive-phase-1-results-for-novel-alzheimer-s-drug-sul-238 2025-07-28T21:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/pluristyx-secures-strategic-investment-to-advance-ipsc-technologies-and-gene-edited-cell-lines 2025-07-28T21:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/federal-court-rules-prep-act-cannot-shield-covid-test-swab-manufacturer-from-patent-infringement-claims 2025-07-28T21:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/global-alzheimer-s-platform-foundation-and-genentech-partner-to-enhance-diversity-in-alzheimer-s-clinical-trials 2025-07-28T21:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/can-fite-biopharma-raises-5-million-in-public-offering-to-fund-cancer-and-inflammatory-disease-drug-development 2025-07-28T21:28:23+00:00 hourly 0.9 https://trial.medpath.com/news/qualigen-therapeutics-secures-4-5-million-in-series-a-3-preferred-stock-financing-to-advance-cancer-therapeutics-pipeline 2025-07-28T21:28:17+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-pointer-study-demonstrates-structured-lifestyle-interventions-significantly-improve-cognitive-function-in-at-risk-older-adults 2025-07-28T21:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/avacta-completes-transition-to-pure-play-therapeutics-with-ps2-2m-coris-sale 2025-07-28T17:39:37+00:00 hourly 0.9 https://trial.medpath.com/news/oncoc4-s-onc-841-shows-promise-as-first-in-class-alzheimer-s-disease-immunotherapy-in-preclinical-studies 2025-07-28T17:39:27+00:00 hourly 0.9 https://trial.medpath.com/news/zetagen-therapeutics-secures-uspto-patents-for-novel-intratumoral-breast-cancer-platform 2025-07-28T17:38:19+00:00 hourly 0.9 https://trial.medpath.com/news/cumulus-neuroscience-validates-at-home-digital-biomarkers-show-greater-sensitivity-than-standard-alzheimer-s-assessment-scale 2025-07-28T17:38:17+00:00 hourly 0.9 https://trial.medpath.com/news/isobio-secures-5-million-series-seed-funding-to-advance-antibody-isotope-conjugates-for-cancer-treatment 2025-07-28T17:36:34+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-letter-to-glenmark-pharmaceuticals-following-manufacturing-quality-violations 2025-07-28T17:35:47+00:00 hourly 0.9 https://trial.medpath.com/news/aim-immunotech-reports-promising-mid-year-results-from-phase-2-pancreatic-cancer-combination-therapy-study 2025-07-28T17:34:50+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-drug-sb431542-shows-triple-action-antiviral-efficacy-against-covid-19-in-preclinical-studies 2025-07-28T17:34:34+00:00 hourly 0.9 https://trial.medpath.com/news/acclaim-trial-completes-enrollment-eight-months-ahead-of-schedule-for-colorectal-liver-metastases-study 2025-07-28T17:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/angiodynamics-launches-ambition-btk-trial-for-critical-limb-ischemia-treatment-using-auryon-laser-technology 2025-07-28T17:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/abelacimab-shows-low-bleeding-rates-in-phase-2-periprocedural-trial-may-simplify-anticoagulation-management 2025-07-28T17:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/renovorx-launches-multi-center-panther-registry-study-to-evaluate-real-world-safety-of-renovocath-device 2025-07-28T17:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/filgotinib-meets-primary-endpoint-in-phase-3-trial-for-axial-spondyloarthritis 2025-07-28T13:39:32+00:00 hourly 0.9 https://trial.medpath.com/news/china-medical-system-secures-nmpa-acceptance-for-zunvyl-alzheimer-s-drug-application 2025-07-28T13:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-bone-mineral-density-as-primary-endpoint-for-entera-bio-s-oral-osteoporosis-drug-phase-3-trial 2025-07-28T13:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/onconic-therapeutics-advances-nesuparib-to-phase-2-trials-for-pancreatic-cancer-treatment 2025-07-28T13:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-weathers-sarepta-partnership-turbulence-as-11-billion-rnai-deal-faces-market-scrutiny 2025-07-28T13:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-secures-12-billion-partnership-with-hengrui-for-12-drug-development-portfolio 2025-07-28T13:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-partners-with-re-vana-for-1b-extended-release-eye-therapy-development 2025-07-28T13:30:29+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-study-shows-can-fite-s-piclidenoson-restores-function-in-vascular-dementia-model 2025-07-28T13:29:40+00:00 hourly 0.9 https://trial.medpath.com/news/zilbrysq-market-projected-to-grow-21-64-annually-through-2030-following-fda-approval-for-myasthenia-gravis 2025-07-28T13:28:50+00:00 hourly 0.9 https://trial.medpath.com/news/quanterix-launches-first-to-market-p-tau-205-and-p-tau-212-assays-for-alzheimer-s-disease-research 2025-07-28T13:28:30+00:00 hourly 0.9 https://trial.medpath.com/news/zymeworks-receives-fda-clearance-for-zw251-novel-glypican-3-targeted-adc-for-hepatocellular-carcinoma 2025-07-28T13:27:37+00:00 hourly 0.9 https://trial.medpath.com/news/artcline-reaches-100-patient-milestone-in-septic-shock-immune-cell-therapy-trial 2025-07-28T13:27:24+00:00 hourly 0.9 https://trial.medpath.com/news/diverse-biotech-secures-patents-for-novel-antibody-cannabinoid-and-antibiotic-cannabinoid-conjugates 2025-07-28T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/transgene-and-bioinvent-to-present-updated-bt-001-oncolytic-virus-data-at-esmo-2025 2025-07-28T09:27:12+00:00 hourly 0.9 https://trial.medpath.com/news/ivonescimab-demonstrates-superior-efficacy-in-phase-iii-lung-cancer-trials-positioning-for-global-regulatory-approvals 2025-07-28T09:26:26+00:00 hourly 0.9 https://trial.medpath.com/news/kyan-technologies-ex-vivo-platform-demonstrates-clinical-utility-in-relapsed-refractory-non-hodgkin-lymphoma 2025-07-28T09:25:01+00:00 hourly 0.9 https://trial.medpath.com/news/robles-bioceutics-partners-with-innovigen-to-scale-production-of-senolytic-enhanced-skincare 2025-07-28T08:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-rules-against-roche-in-pertuzumab-patent-disclosure-case-clarifies-section-104a-requirements-for-biologics 2025-07-28T05:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/indian-drug-regulator-orders-enhanced-ndma-monitoring-for-ranitidine-amid-cancer-concerns 2025-07-28T05:28:54+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-secures-12-5-billion-deal-with-hengrui-for-copd-drug-and-11-additional-programs 2025-07-28T05:28:42+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-xpovio-for-second-line-multiple-myeloma-treatment-based-on-phase-iii-bench-trial 2025-07-28T05:27:49+00:00 hourly 0.9 https://trial.medpath.com/news/osr-holdings-acquires-korean-non-invasive-glucose-monitoring-pioneer-woori-io 2025-07-28T00:57:52+00:00 hourly 0.9 https://trial.medpath.com/news/cuhk-develops-magnetic-microcatheter-for-precise-treatment-of-acute-ischemic-stroke 2025-07-28T00:57:47+00:00 hourly 0.9 https://trial.medpath.com/news/roche-launches-clinical-trial-for-trontinemab-to-prevent-alzheimer-s-disease 2025-07-27T21:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/combination-cardiovascular-therapies-show-promise-in-slowing-cognitive-decline-and-reducing-dementia-pathology 2025-07-27T21:24:55+00:00 hourly 0.9 https://trial.medpath.com/news/immunoact-achieves-profitability-with-india-s-first-car-t-therapy-treating-over-350-cancer-patients 2025-07-27T21:24:49+00:00 hourly 0.9 https://trial.medpath.com/news/colorcon-opens-state-of-the-art-film-coating-manufacturing-facility-in-malaysia-to-strengthen-asia-pacific-supply-chain 2025-07-27T21:24:33+00:00 hourly 0.9 https://trial.medpath.com/news/granules-india-ceo-dr-k-v-sitaram-rao-announces-resignation-effective-july-2025 2025-07-27T17:14:24+00:00 hourly 0.9 https://trial.medpath.com/news/caspofungin-trough-concentrations-above-3-58-mg-ml-linked-to-improved-clinical-outcomes-in-retrospective-study 2025-07-27T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/rigicon-initiates-ausome-study-for-artificial-urinary-sphincter-fda-approval 2025-07-27T13:20:58+00:00 hourly 0.9 https://trial.medpath.com/news/fecal-microbiota-transplantation-shows-safety-and-tolerability-in-six-month-parkinson-s-disease-pilot-study 2025-07-27T09:23:23+00:00 hourly 0.9 https://trial.medpath.com/news/bangladesh-pharmaceutical-companies-risk-losing-royalty-free-access-to-15-biologic-drugs-due-to-regulatory-delays 2025-07-27T01:20:09+00:00 hourly 0.9 https://trial.medpath.com/news/india-maintains-firm-stance-against-patent-evergreening-in-global-trade-negotiations 2025-07-27T01:20:04+00:00 hourly 0.9 https://trial.medpath.com/news/novel-therapeutic-strategies-show-promise-for-overcoming-immunotherapy-resistant-nsclc 2025-07-27T01:19:25+00:00 hourly 0.9 https://trial.medpath.com/news/nice-expands-nhs-funding-for-astrazeneca-s-lokelma-to-include-outpatient-care 2025-07-27T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/nppa-committee-identifies-patent-discrepancies-in-intas-clozapine-er-pricing-application 2025-07-26T21:24:52+00:00 hourly 0.9 https://trial.medpath.com/news/applied-dna-sciences-secures-600000-follow-on-order-for-cancer-diagnostic-component 2025-07-26T17:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/ptab-director-denies-amgen-s-ipr-challenges-against-bristol-myers-squibb-s-opdivo-patents-based-on-settled-expectations 2025-07-26T17:24:16+00:00 hourly 0.9 https://trial.medpath.com/news/cytodyn-files-100m-mixed-shelf-offering-to-advance-leronlimab-through-phase-iii-trials 2025-07-26T17:24:11+00:00 hourly 0.9 https://trial.medpath.com/news/indoco-remedies-receives-eu-gmp-certification-for-sterile-manufacturing-facility-in-goa 2025-07-26T17:23:43+00:00 hourly 0.9 https://trial.medpath.com/news/menopausal-hormone-therapy-shows-persistent-bone-protection-despite-temporary-risk-increase-after-discontinuation 2025-07-26T17:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/io-biotech-s-cylembio-cancer-vaccine-misses-primary-endpoint-in-phase-3-melanoma-trial 2025-07-26T14:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/ghana-receives-africa-s-first-novaseq-x-plus-sequencer-to-address-cancer-care-disparities 2025-07-26T13:26:57+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-part-b-drug-price-negotiations-may-restrict-patient-access-to-cancer-and-autoimmune-treatments 2025-07-26T09:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/ut-sanofi-partnership-develops-ai-model-to-accelerate-mrna-therapeutic-discovery 2025-07-26T09:25:34+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-s-zurzuvae-receives-ema-panel-recommendation-for-postpartum-depression-treatment 2025-07-26T09:25:12+00:00 hourly 0.9 https://trial.medpath.com/news/community-oncologist-highlights-persistent-access-barriers-to-targeted-breast-cancer-therapies 2025-07-26T09:24:46+00:00 hourly 0.9 https://trial.medpath.com/news/novel-dental-floss-based-vaccine-delivery-system-shows-promise-against-influenza-in-preclinical-study 2025-07-26T05:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-rejects-roche-s-bid-to-force-zydus-to-disclose-sigrima-manufacturing-process 2025-07-26T05:23:29+00:00 hourly 0.9 https://trial.medpath.com/news/sen-jam-pharmaceutical-initiates-phase-2-trial-for-first-in-class-hangover-prevention-therapy-sjp-001 2025-07-26T05:23:22+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-clearside-biomedical-s-xipere-for-uveitic-macular-edema-treatment 2025-07-26T05:23:14+00:00 hourly 0.9 https://trial.medpath.com/news/omeros-raises-22-million-in-direct-offering-to-fund-narsoplimab-development-amid-regulatory-review 2025-07-26T05:22:37+00:00 hourly 0.9 https://trial.medpath.com/news/uva-launches-first-of-its-kind-psilocybin-trial-for-prolonged-grief-disorder 2025-07-26T05:22:17+00:00 hourly 0.9 https://trial.medpath.com/news/multidisciplinary-approach-and-technology-integration-show-promise-for-addressing-hidradenitis-suppurativa-care-disparities 2025-07-26T05:22:07+00:00 hourly 0.9 https://trial.medpath.com/news/agenus-advances-bot-bal-combination-therapy-with-phase-3-battman-trial-launch-for-metastatic-colorectal-cancer 2025-07-26T05:21:38+00:00 hourly 0.9 https://trial.medpath.com/news/new-jersey-senator-advocates-for-state-led-healthcare-ai-implementation-and-rural-health-investment 2025-07-26T05:21:35+00:00 hourly 0.9 https://trial.medpath.com/news/france-prepares-major-drug-pricing-reforms-as-ceps-report-due-july-2025 2025-07-26T02:57:38+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-genomic-profiling-shows-cost-neutrality-despite-underutilization-in-advanced-cancer-care 2025-07-26T02:57:25+00:00 hourly 0.9 https://trial.medpath.com/news/early-onset-gastrointestinal-cancers-surge-globally-rising-faster-than-any-other-cancer-type-in-young-adults 2025-07-26T02:57:13+00:00 hourly 0.9 https://trial.medpath.com/news/atai-life-sciences-schizophrenia-cognitive-drug-inidascamine-fails-primary-endpoint-in-phase-2-trial 2025-07-26T01:01:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-upgrades-recall-of-160000-bottles-of-levothyroxine-due-to-subpotent-active-ingredients 2025-07-26T01:01:35+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-show-promise-for-pcos-treatment-in-early-studies 2025-07-26T01:01:06+00:00 hourly 0.9 https://trial.medpath.com/news/recognify-s-inidascamine-misses-primary-endpoint-in-phase-2b-trial-for-schizophrenia-associated-cognitive-impairment 2025-07-26T00:59:40+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-approval-of-aqneursa-for-niemann-pick-type-c-disease-treatment 2025-07-26T00:59:03+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-approves-cabometyx-for-advanced-pancreatic-neuroendocrine-tumors 2025-07-26T00:58:19+00:00 hourly 0.9 https://trial.medpath.com/news/centanafadine-shows-promise-for-pediatric-and-adolescent-adhd-in-phase-3-trials 2025-07-25T21:22:27+00:00 hourly 0.9 https://trial.medpath.com/news/seca-trial-challenges-routine-aspirin-cessation-in-chronic-subdural-hematoma-surgery 2025-07-25T21:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/insmed-opens-cambridge-r-d-facility-focused-on-synthetic-rescue-platform-for-rare-diseases 2025-07-25T21:21:28+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-pipeline-analysis-reveals-200-investigational-drugs-for-metastatic-hormone-refractory-prostate-cancer 2025-07-25T21:20:28+00:00 hourly 0.9 https://trial.medpath.com/news/naip-breaks-ground-on-state-of-the-art-pharmaceutical-research-centre-in-nigeria-s-anambra-state 2025-07-25T21:19:43+00:00 hourly 0.9 https://trial.medpath.com/news/cilcare-secures-eur50000-grant-for-3d-bioprinted-human-model-to-advance-hearing-loss-drug-development 2025-07-25T21:19:38+00:00 hourly 0.9 https://trial.medpath.com/news/leveragen-and-propeller-bio-form-strategic-partnership-to-advance-next-generation-antibody-discovery-platform 2025-07-25T21:19:12+00:00 hourly 0.9 https://trial.medpath.com/news/multiple-cancer-clinical-trials-advance-with-remote-study-models-and-novel-therapeutics 2025-07-25T21:17:16+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-drugs-show-promise-for-asthma-control-in-obese-patients-beyond-weight-loss-benefits 2025-07-25T17:30:18+00:00 hourly 0.9 https://trial.medpath.com/news/phio-pharmaceuticals-secures-u-s-manufacturing-partnership-for-pd-1-silencing-cancer-therapy-ph-762 2025-07-25T17:28:58+00:00 hourly 0.9 https://trial.medpath.com/news/india-uk-free-trade-agreement-raises-concerns-over-access-to-affordable-medicines 2025-07-25T17:27:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-complete-response-letters-highlight-growing-cmc-challenges-in-immunotherapy-development 2025-07-25T17:26:17+00:00 hourly 0.9 https://trial.medpath.com/news/lyell-immunopharma-secures-100-million-private-placement-to-advance-car-t-cell-therapy-development 2025-07-25T17:26:06+00:00 hourly 0.9 https://trial.medpath.com/news/cannabis-use-disorder-pipeline-shows-promise-with-novel-therapies-in-development 2025-07-25T17:26:01+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-appoints-astrazeneca-s-cristian-massacesi-as-new-chief-medical-officer 2025-07-25T17:25:52+00:00 hourly 0.9 https://trial.medpath.com/news/european-regulators-recommend-approval-of-vorasidenib-for-idh-mutant-grade-2-glioma 2025-07-25T17:24:27+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-s-repatha-faces-safety-scrutiny-as-heroic-study-evaluates-cardiovascular-benefits 2025-07-25T17:23:54+00:00 hourly 0.9 https://trial.medpath.com/news/aiims-led-study-demonstrates-equal-efficacy-of-three-two-drug-hypertension-combinations-in-south-asian-patients 2025-07-25T17:23:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-doptelet-for-pediatric-immune-thrombocytopenia-with-new-sprinkle-formulation 2025-07-25T17:23:31+00:00 hourly 0.9 https://trial.medpath.com/news/tirzepatide-shows-greater-benefits-in-higher-bmi-patients-with-heart-failure-and-obesity-summit-trial-analysis-reveals 2025-07-25T13:34:26+00:00 hourly 0.9 https://trial.medpath.com/news/believer-meats-becomes-first-foreign-company-to-secure-fda-clearance-for-cultivated-chicken 2025-07-25T13:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/kintor-pharma-s-kx-826-hair-loss-treatment-achieves-primary-endpoint-in-phase-ii-trial 2025-07-25T13:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/plant-virus-nanoparticles-show-promise-as-novel-cancer-immunotherapy-in-preclinical-studies 2025-07-25T13:28:34+00:00 hourly 0.9 https://trial.medpath.com/news/european-regulators-recommend-expanding-novo-nordisk-s-alhemo-for-hemophilia-a-and-b-without-inhibitors 2025-07-25T13:27:54+00:00 hourly 0.9 https://trial.medpath.com/news/milliporesigma-and-washington-university-strengthen-90-year-partnership-to-accelerate-life-sciences-innovation 2025-07-25T13:27:35+00:00 hourly 0.9 https://trial.medpath.com/news/beone-medicines-expands-beijing-r-d-center-to-accelerate-oncology-drug-development 2025-07-25T13:25:34+00:00 hourly 0.9 https://trial.medpath.com/news/adocia-s-ultra-rapid-insulin-biochaperone-lispro-meets-primary-endpoint-in-phase-3-trial-for-type-2-diabetes 2025-07-25T13:25:30+00:00 hourly 0.9 https://trial.medpath.com/news/fermented-stevia-extract-shows-selective-cytotoxicity-against-pancreatic-cancer-cells-in-laboratory-study 2025-07-25T13:25:22+00:00 hourly 0.9 https://trial.medpath.com/news/precirix-receives-fda-clearance-to-begin-phase-1-trial-of-cam-fap-ac-225-targeted-alpha-therapy 2025-07-25T13:24:24+00:00 hourly 0.9 https://trial.medpath.com/news/sumitomo-corporation-partners-with-ai-startup-airato-to-revolutionize-cancer-radiation-therapy-planning 2025-07-25T13:24:17+00:00 hourly 0.9 https://trial.medpath.com/news/atrial-fibrillation-pipeline-shows-robust-development-with-15-novel-therapies-from-leading-pharmaceutical-companies 2025-07-25T10:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/eu-regulatory-approval-advances-pfizer-biontech-lp-8-1-adapted-covid-19-vaccine-for-2025-2026-season 2025-07-25T09:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/everest-medicines-raises-hk-1-57-billion-to-accelerate-ai-mrna-platform-and-pipeline-development 2025-07-25T09:22:36+00:00 hourly 0.9 https://trial.medpath.com/news/ocugen-initiates-phase-2-3-gardian3-trial-for-stargardt-disease-gene-therapy 2025-07-25T05:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/rocket-pharmaceuticals-cuts-30-of-workforce-refocuses-on-cardiovascular-gene-therapies 2025-07-25T05:24:26+00:00 hourly 0.9 https://trial.medpath.com/news/tga-investigates-15-fold-spike-in-vyvanse-adverse-event-reports-amid-social-media-influence 2025-07-25T05:24:16+00:00 hourly 0.9 https://trial.medpath.com/news/new-study-links-depo-provera-to-doubled-brain-tumor-risk-as-pfizer-faces-over-1200-lawsuits 2025-07-25T05:23:02+00:00 hourly 0.9 https://trial.medpath.com/news/leads-biolabs-raises-189-million-in-hong-kong-ipo-advances-first-in-class-4-1bb-immunotherapy 2025-07-25T05:22:45+00:00 hourly 0.9 https://trial.medpath.com/news/absci-raises-50-million-to-advance-ai-driven-drug-discovery-platform-and-internal-pipeline 2025-07-25T05:22:38+00:00 hourly 0.9 https://trial.medpath.com/news/epic-trial-shows-immunotherapy-extends-survival-in-advanced-penile-cancer-patients 2025-07-25T05:22:15+00:00 hourly 0.9 https://trial.medpath.com/news/procept-biorobotics-expands-prostate-cancer-trial-to-outpatient-setting-with-first-asc-procedures 2025-07-25T01:30:23+00:00 hourly 0.9 https://trial.medpath.com/news/magnetically-steerable-drug-delivery-vesicles-show-promise-for-precision-cancer-treatment 2025-07-25T01:28:19+00:00 hourly 0.9 https://trial.medpath.com/news/coya-therapeutics-coya-303-demonstrates-anti-inflammatory-effects-in-preclinical-alzheimer-s-model 2025-07-25T01:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/janux-therapeutics-advances-multi-platform-pipeline-with-novel-arm-technology-for-autoimmune-diseases 2025-07-25T01:25:49+00:00 hourly 0.9 https://trial.medpath.com/news/nextcure-s-anti-siglec-15-antibody-nc605-shows-promise-for-osteogenesis-imperfecta-treatment-in-preclinical-study 2025-07-25T01:25:44+00:00 hourly 0.9 https://trial.medpath.com/news/insmed-s-brensocatib-wins-fda-approval-as-first-treatment-for-non-cystic-fibrosis-bronchiectasis 2025-07-25T01:25:40+00:00 hourly 0.9 https://trial.medpath.com/news/pedal-study-demonstrates-prospera-kidney-test-accurately-predicts-long-term-outcomes-after-transplant-rejection 2025-07-25T01:25:10+00:00 hourly 0.9 https://trial.medpath.com/news/hydroxychloroquine-shows-promise-for-kidney-protection-in-primary-glomerular-disease-and-lupus-nephritis 2025-07-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/iran-israel-conflict-disrupts-global-clinical-trial-landscape-as-india-overtakes-iran-in-q2-2025 2025-07-24T21:29:40+00:00 hourly 0.9 https://trial.medpath.com/news/stevanato-group-secures-eur200-million-financing-to-expand-biologics-manufacturing-capacity 2025-07-24T21:29:25+00:00 hourly 0.9 https://trial.medpath.com/news/novel-bispecific-antibody-xmab30819-shows-promise-in-advanced-clear-cell-renal-cell-carcinoma 2025-07-24T21:29:03+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-initiates-phase-clinical-trial-for-bay3018250-in-deep-vein-thrombosis-treatment 2025-07-24T21:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/biocardia-seeks-japan-pmda-approval-for-cardiamp-cell-therapy-in-heart-failure-treatment 2025-07-24T21:25:52+00:00 hourly 0.9 https://trial.medpath.com/news/roche-discontinues-obesity-drug-ct-173-from-2-7b-carmot-acquisition-citing-lack-of-competitiveness 2025-07-24T21:25:49+00:00 hourly 0.9 https://trial.medpath.com/news/gate-bioscience-partners-with-lilly-in-856-million-deal-to-develop-novel-molecular-gate-therapeutics 2025-07-24T21:25:21+00:00 hourly 0.9 https://trial.medpath.com/news/gnt-pharma-advances-first-in-class-dual-action-stroke-therapy-nelonemdaz-to-global-phase-3-trials 2025-07-24T21:24:33+00:00 hourly 0.9 https://trial.medpath.com/news/cdx-diagnostics-receives-fda-breakthrough-device-designation-for-ai-powered-wats3d-esophageal-cancer-diagnostic-system 2025-07-24T21:24:26+00:00 hourly 0.9 https://trial.medpath.com/news/tcg-labs-soleil-raises-400m-to-build-single-asset-biotech-startups-for-strategic-partnerships 2025-07-24T21:23:59+00:00 hourly 0.9 https://trial.medpath.com/news/medcomms-experts-acquires-nexgen-healthcare-communications-to-expand-global-medical-communications-platform 2025-07-24T19:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/celularity-s-pda-002-shows-promise-in-phase-2-trial-for-diabetic-foot-ulcers-with-peripheral-artery-disease 2025-07-24T17:44:47+00:00 hourly 0.9 https://trial.medpath.com/news/krystal-biotech-s-kb304-gene-therapy-achieves-100-response-rate-in-phase-1-decollete-wrinkle-trial 2025-07-24T17:41:55+00:00 hourly 0.9 https://trial.medpath.com/news/ideaya-biosciences-to-present-phase-2-darovasertib-data-for-uveal-melanoma-at-esmo-2025 2025-07-24T17:41:22+00:00 hourly 0.9 https://trial.medpath.com/news/roche-explores-direct-to-consumer-drug-sales-model-to-reduce-us-patient-costs 2025-07-24T17:41:20+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trials-advance-novel-treatments-for-androgenetic-alopecia-as-researchers-target-30-year-treatment-gap 2025-07-24T17:41:16+00:00 hourly 0.9 https://trial.medpath.com/news/sanner-opens-first-u-s-manufacturing-facility-in-north-carolina-expanding-global-cdmo-operations 2025-07-24T17:39:11+00:00 hourly 0.9 https://trial.medpath.com/news/mass-general-brigham-study-links-glipizide-to-13-higher-cardiovascular-risk-in-type-2-diabetes-patients 2025-07-24T17:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/astra-therapeutics-secures-chf-7-75-million-to-develop-novel-anti-parasitic-drugs-for-veterinary-medicine 2025-07-24T17:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-partners-with-matchpoint-therapeutics-in-1-billion-anti-inflammatory-drug-development-deal 2025-07-24T17:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/biostate-ai-expands-global-precision-medicine-platform-through-strategic-partnerships-in-us-china-and-india 2025-07-24T17:29:30+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-study-shows-ibogaine-dramatically-reduces-ptsd-and-depression-in-veterans-with-traumatic-brain-injury 2025-07-24T17:27:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-priority-review-for-flibanserin-expansion-to-postmenopausal-women-with-hsdd 2025-07-24T17:26:57+00:00 hourly 0.9 https://trial.medpath.com/news/maryland-scientists-develop-shelf-stable-synthetic-blood-for-emergency-medicine 2025-07-24T17:26:04+00:00 hourly 0.9 https://trial.medpath.com/news/intranasal-insulin-successfully-reaches-memory-centers-in-alzheimer-s-brain-imaging-study 2025-07-24T17:25:21+00:00 hourly 0.9 https://trial.medpath.com/news/topical-immunotherapy-shows-promise-for-severe-alopecia-areata-despite-variable-response-rates 2025-07-24T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-reports-strong-q2-2025-results-with-jakafi-growth-and-new-drug-approvals 2025-07-24T15:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/ivermectin-mass-treatment-reduces-malaria-transmission-by-26-in-landmark-bohemia-trial 2025-07-24T13:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/medicinova-advances-dual-pipeline-strategy-with-novel-therapeutics-for-neurological-and-metabolic-disorders 2025-07-24T13:27:15+00:00 hourly 0.9 https://trial.medpath.com/news/turbine-partners-with-astrazeneca-to-accelerate-adc-discovery-using-ai-powered-virtual-disease-models 2025-07-24T13:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/kling-bio-partners-with-sanofi-to-develop-next-generation-antiviral-antibodies-using-proprietary-b-cell-platform 2025-07-24T13:26:10+00:00 hourly 0.9 https://trial.medpath.com/news/harvard-ai-model-pdgrapher-accelerates-drug-discovery-by-predicting-cellular-disease-reversal 2025-07-24T13:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/medicinova-nears-completion-of-phase-2-3-als-trial-as-combat-als-study-approaches-full-enrollment 2025-07-24T13:23:38+00:00 hourly 0.9 https://trial.medpath.com/news/annexin-pharmaceuticals-receives-uk-approval-for-phase-2a-study-of-anxv-in-diabetic-retinopathy 2025-07-24T13:23:27+00:00 hourly 0.9 https://trial.medpath.com/news/tulsi-therapeutics-achieves-100-liver-regeneration-in-world-s-first-stem-cell-exosome-therapy-trial 2025-07-24T09:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/epilepsy-drug-pipeline-shows-robust-growth-with-90-therapies-in-development-across-75-companies 2025-07-24T09:23:39+00:00 hourly 0.9 https://trial.medpath.com/news/dna-plasmid-therapy-elenagen-shows-90-success-rate-in-treating-chronic-pain-in-dogs-signals-non-opioid-path-for-human-medicine 2025-07-24T09:23:37+00:00 hourly 0.9 https://trial.medpath.com/news/llama-derived-nanobody-shows-promise-for-schizophrenia-cognitive-symptoms-in-preclinical-study 2025-07-24T09:23:25+00:00 hourly 0.9 https://trial.medpath.com/news/bridging-radiotherapy-shows-promise-in-reducing-car-t-cell-therapy-toxicity-across-b-cell-lymphoma-and-multiple-myeloma 2025-07-24T05:25:41+00:00 hourly 0.9 https://trial.medpath.com/news/aicuris-pritelivir-achieves-superior-efficacy-in-phase-3-trial-for-refractory-hsv-in-immunocompromised-patients 2025-07-24T05:11:54+00:00 hourly 0.9 https://trial.medpath.com/news/quanta-therapeutics-advances-kras-g12d-inhibitor-qtx3034-to-dose-expansion-phase-following-positive-safety-data 2025-07-24T01:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-and-astellas-successfully-defend-prostate-cancer-drug-patent-against-generic-challenge 2025-07-24T01:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/hillhurst-biopharmaceuticals-initiates-phase-2a-trial-of-oral-carbon-monoxide-therapy-for-sickle-cell-disease 2025-07-24T01:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/australia-s-national-reconstruction-fund-invests-150m-in-brandon-capital-to-retain-biotech-innovation-onshore 2025-07-24T01:26:56+00:00 hourly 0.9 https://trial.medpath.com/news/abivax-raises-747-5-million-in-public-offering-to-advance-ulcerative-colitis-drug-development 2025-07-24T01:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-becomes-first-country-to-enable-point-of-care-manufacturing-for-personalized-therapies 2025-07-23T21:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/qu-biologics-completes-enrollment-in-phase-2-trial-testing-novel-immunomodulator-for-age-related-immune-decline 2025-07-23T21:29:10+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-wins-patent-battle-against-novo-nordisk-over-generic-wegovy 2025-07-23T21:27:51+00:00 hourly 0.9 https://trial.medpath.com/news/federal-court-dismisses-whistleblower-patent-fraud-lawsuit-against-valeant-and-salix-over-ulcerative-colitis-drug-apriso 2025-07-23T21:27:44+00:00 hourly 0.9 https://trial.medpath.com/news/autoantibodies-emerge-as-key-predictors-of-cancer-immunotherapy-response-boosting-effectiveness-up-to-10-fold 2025-07-23T21:27:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-advanced-uronav-system-for-precision-focal-therapy-in-prostate-cancer 2025-07-23T21:27:35+00:00 hourly 0.9 https://trial.medpath.com/news/stem-cell-therapy-shows-promise-for-fertility-restoration-in-women-with-ovarian-failure 2025-07-23T21:27:19+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-researchers-develop-gene-therapy-to-reactivate-silent-genes-in-rett-syndrome 2025-07-23T21:26:49+00:00 hourly 0.9 https://trial.medpath.com/news/legacy-healthcare-s-cinainu-shows-sustained-hair-regrowth-in-pediatric-alopecia-areata-phase-2-3-trial 2025-07-23T21:26:41+00:00 hourly 0.9 https://trial.medpath.com/news/atopic-dermatitis-market-poised-for-four-fold-growth-by-2034-driven-by-novel-il-13-inhibitor-approvals 2025-07-23T21:25:03+00:00 hourly 0.9 https://trial.medpath.com/news/flatiron-health-triples-global-oncology-research-network-expanding-real-world-data-access-across-three-countries 2025-07-23T21:24:17+00:00 hourly 0.9 https://trial.medpath.com/news/ucsf-chemists-overcome-solubility-issues-in-next-generation-malaria-drug-through-molecular-redesign 2025-07-23T17:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/ai-guided-drug-lp-284-achieves-complete-response-in-treatment-resistant-lymphoma-patient 2025-07-23T17:31:54+00:00 hourly 0.9 https://trial.medpath.com/news/long-acting-anti-tslp-antibody-hbm9378-win378-enters-global-phase-2-trial-for-asthma-treatment 2025-07-23T17:29:56+00:00 hourly 0.9 https://trial.medpath.com/news/neuroone-receives-uspto-patent-approval-for-novel-neural-probe-manufacturing-technology 2025-07-23T17:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/huonslab-secures-key-patent-for-albumin-free-hyaluronidase-formulation-advances-toward-2026-market-authorization 2025-07-23T17:29:06+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-restructures-executive-leadership-with-three-key-appointments-to-drive-growth-in-oncology-and-rare-disease 2025-07-23T17:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/former-poseida-ceo-kristin-yarema-named-to-lead-ikena-inmagene-merger-as-companies-advance-anti-ox40-therapy 2025-07-23T17:28:46+00:00 hourly 0.9 https://trial.medpath.com/news/an2-therapeutics-partners-with-dndi-to-advance-oral-chagas-disease-treatment-an2-502998 2025-07-23T17:28:32+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-safety-data-support-mvasi-biosimilar-as-viable-alternative-for-retinal-disease-treatment 2025-07-23T17:27:57+00:00 hourly 0.9 https://trial.medpath.com/news/epicore-biosystems-secures-1-2m-military-contract-for-smart-hydration-wearables 2025-07-23T17:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/igc-pharma-unveils-ai-powered-alzheimer-s-platforms-at-aaic-2025 2025-07-23T17:27:22+00:00 hourly 0.9 https://trial.medpath.com/news/oncoc4-advances-pd-1-vegf-bispecific-antibody-ai-081-to-phase-2-trial-following-promising-early-efficacy-data 2025-07-23T17:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/radiation-therapy-overcomes-primary-resistance-to-pembrolizumab-in-immunologically-cold-nsclc 2025-07-23T17:26:26+00:00 hourly 0.9 https://trial.medpath.com/news/inotrem-s-precision-medicine-strategy-shows-breakthrough-results-for-septic-shock-treatment-with-nangibotide 2025-07-23T17:26:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-avidity-s-del-zota-for-duchenne-muscular-dystrophy 2025-07-23T17:26:03+00:00 hourly 0.9 https://trial.medpath.com/news/cepi-launches-two-major-initiatives-to-accelerate-vaccine-development-and-regulatory-approval-in-disease-outbreaks 2025-07-23T17:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/global-clinical-trials-landscape-for-alopecia-universalis-reveals-growing-research-activity-across-major-pharmaceutical-companies 2025-07-23T17:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/cycle-pharmaceuticals-secures-exclusive-u-s-rights-to-phyrago-novel-dasatinib-formulation-for-leukemia-treatment 2025-07-23T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/apollo-hospitals-and-siemens-healthineers-launch-ai-driven-research-collaboration-for-liver-disease-diagnostics-in-india 2025-07-23T13:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-launches-beova-tablets-for-overactive-bladder-treatment-in-thailand 2025-07-23T13:29:09+00:00 hourly 0.9 https://trial.medpath.com/news/crown-bioscience-san-diego-receives-clia-certification-to-expand-clinical-testing-capabilities 2025-07-23T13:27:52+00:00 hourly 0.9 https://trial.medpath.com/news/iluvien-shows-mixed-results-in-new-day-trial-for-diabetic-macular-edema-treatment 2025-07-23T13:25:44+00:00 hourly 0.9 https://trial.medpath.com/news/c-mic-ii-trial-shows-microcurrent-therapy-significantly-improves-heart-function-in-heart-failure-patients 2025-07-23T13:25:37+00:00 hourly 0.9 https://trial.medpath.com/news/bd-libertas-wearable-injector-enters-first-pharma-sponsored-clinical-trial-for-complex-biologics-delivery 2025-07-23T13:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/bio-usawa-and-servaregmp-partner-to-establish-monoclonal-antibody-manufacturing-in-africa 2025-07-23T13:23:25+00:00 hourly 0.9 https://trial.medpath.com/news/dispatch-bio-emerges-with-216m-to-develop-universal-solid-tumor-immunotherapy 2025-07-23T13:23:12+00:00 hourly 0.9 https://trial.medpath.com/news/dapagliflozin-demonstrates-sustained-cardiovascular-benefits-in-long-term-diabetes-study 2025-07-23T09:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/ghana-fda-and-company-deny-coa-72-hiv-clinical-trial-claims-following-media-misinformation 2025-07-23T09:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/a-forall-launches-direct-commercialization-of-sodium-acetate-injection-to-address-u-s-drug-shortage 2025-07-23T09:23:46+00:00 hourly 0.9 https://trial.medpath.com/news/csl-behring-s-australian-plasma-facility-wins-global-manufacturing-excellence-award-for-advanced-automation 2025-07-23T09:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-biologics-expands-nepexto-biosimilar-to-australian-market-for-autoimmune-disease-treatment 2025-07-23T09:22:30+00:00 hourly 0.9 https://trial.medpath.com/news/ulonivirine-shows-promise-for-once-weekly-hiv-treatment-despite-early-trial-setback 2025-07-23T09:22:28+00:00 hourly 0.9 https://trial.medpath.com/news/syntellix-secures-nmpa-approval-for-bioabsorbable-metallic-implants-in-china-unlocking-1-4-billion-patient-market 2025-07-23T09:21:53+00:00 hourly 0.9 https://trial.medpath.com/news/pfas-forever-chemicals-linked-to-31-increased-risk-of-type-2-diabetes 2025-07-23T09:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/hesperos-achieves-first-digital-twin-of-human-disease-using-malaria-on-a-chip-platform 2025-07-23T05:21:26+00:00 hourly 0.9 https://trial.medpath.com/news/american-gene-technologies-reports-sustained-hiv-reservoir-reduction-in-phase-1-trial-of-agt103-t-cell-therapy 2025-07-23T05:21:24+00:00 hourly 0.9 https://trial.medpath.com/news/kidney-cancer-research-consortium-advances-novel-combination-therapies-through-multi-institutional-collaboration 2025-07-23T02:57:14+00:00 hourly 0.9 https://trial.medpath.com/news/avalyn-pharma-raises-100m-to-advance-inhaled-pulmonary-fibrosis-therapies 2025-07-23T01:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/novel-csf-biomarkers-chit1-and-ddah1-may-predict-aria-risk-in-alzheimer-s-patients-receiving-anti-amyloid-therapies 2025-07-23T01:27:19+00:00 hourly 0.9 https://trial.medpath.com/news/tharimmune-raises-1-74-million-to-advance-immunology-and-oncology-pipeline 2025-07-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-3d-printed-epilepsy-drug-for-feeding-tube-administration 2025-07-22T21:29:34+00:00 hourly 0.9 https://trial.medpath.com/news/pacira-biosciences-partners-with-johnson-johnson-to-expand-zilretta-access-for-osteoarthritis-knee-pain 2025-07-22T21:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/concentra-biosciences-acquires-iteos-therapeutics-for-10-05-per-share-following-tigit-program-failure 2025-07-22T21:24:51+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-researchers-develop-radiation-free-stem-cell-transplant-protocol-for-fanconi-anemia-patients 2025-07-22T21:24:21+00:00 hourly 0.9 https://trial.medpath.com/news/stride-immunotherapy-achieves-unprecedented-19-6-five-year-survival-rate-in-advanced-liver-cancer 2025-07-22T21:23:44+00:00 hourly 0.9 https://trial.medpath.com/news/subcutaneous-daratumumab-formulation-reduces-treatment-time-and-premedication-requirements-in-multiple-myeloma 2025-07-22T21:23:36+00:00 hourly 0.9 https://trial.medpath.com/news/hmnc-brain-health-and-spruce-biosciences-launch-phase-2-trial-for-precision-depression-treatment 2025-07-22T21:23:09+00:00 hourly 0.9 https://trial.medpath.com/news/precision-genomic-profiling-reveals-multiple-molecular-diagnoses-in-gaucher-disease-patients-with-atypical-presentations 2025-07-22T21:22:28+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-shows-adalimumab-biosimilar-ibi303-matches-humira-efficacy-with-superior-cost-benefits-in-ankylosing-spondylitis 2025-07-22T21:21:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-replimune-s-melanoma-drug-amid-evolving-regulatory-standards 2025-07-22T21:21:04+00:00 hourly 0.9 https://trial.medpath.com/news/nanoknife-system-shows-promise-for-prostate-cancer-treatment-in-preserve-trial 2025-07-22T21:20:50+00:00 hourly 0.9 https://trial.medpath.com/news/sintx-technologies-submits-fda-510-k-for-silicon-nitride-foot-and-ankle-implants 2025-07-22T21:20:46+00:00 hourly 0.9 https://trial.medpath.com/news/wuxi-biologics-achieves-100-fda-inspection-success-rate-with-five-facilities-passing-pre-license-review 2025-07-22T17:36:17+00:00 hourly 0.9 https://trial.medpath.com/news/radiopharm-theranostics-appoints-leading-prostate-cancer-expert-dr-oliver-sartor-to-scientific-advisory-board 2025-07-22T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-approves-phase-iii-trials-for-two-novel-cardiovascular-fixed-dose-combinations 2025-07-22T17:30:18+00:00 hourly 0.9 https://trial.medpath.com/news/biovie-strengthens-board-with-neuroscience-and-finance-veterans-as-bezisterim-advances-through-phase-2-trials 2025-07-22T17:30:14+00:00 hourly 0.9 https://trial.medpath.com/news/cgt-catapult-invests-in-spliceor-s-trans-splicing-gene-therapy-platform-for-liver-cancer 2025-07-22T17:29:11+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-receives-gene-therapy-for-ultra-rare-nedamss-disease-in-record-13-month-timeline 2025-07-22T17:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/ixico-secures-full-data-rights-to-landmark-bio-hermes-002-alzheimer-s-study-through-strategic-gap-partnership 2025-07-22T17:28:21+00:00 hourly 0.9 https://trial.medpath.com/news/fda-discontinues-rare-pediatric-disease-designation-program-despite-rising-approval-trends 2025-07-22T17:26:41+00:00 hourly 0.9 https://trial.medpath.com/news/alto-neuroscience-faces-class-action-lawsuit-following-alto-100-phase-2b-trial-failure 2025-07-22T17:26:39+00:00 hourly 0.9 https://trial.medpath.com/news/medunik-usa-expands-siklos-r-medicaid-coverage-to-37-states-improving-access-for-sickle-cell-disease-patients 2025-07-22T17:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/coriolis-pharma-invests-10-million-in-north-carolina-laboratory-to-expand-biopharmaceutical-development-services 2025-07-22T17:25:57+00:00 hourly 0.9 https://trial.medpath.com/news/q3-2025-biopharma-catalyst-monitor-highlights-18-key-fda-decisions-and-clinical-trial-milestones 2025-07-22T17:25:47+00:00 hourly 0.9 https://trial.medpath.com/news/surgivance-secures-2-2m-nih-grant-to-advance-direct-to-digital-pathology-platform 2025-07-22T17:25:43+00:00 hourly 0.9 https://trial.medpath.com/news/seres-therapeutics-appoints-co-ceos-as-company-seeks-partnerships-for-ser-155-development 2025-07-22T17:25:36+00:00 hourly 0.9 https://trial.medpath.com/news/estonian-biotech-aio-secures-eur1m-grant-to-develop-sustainable-cosmetics-ingredients-through-yeast-fermentation 2025-07-22T17:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/answer-als-launches-ai-powered-drug-discovery-initiative-to-accelerate-als-treatment-development 2025-07-22T17:24:55+00:00 hourly 0.9 https://trial.medpath.com/news/sutro-biopharma-partners-with-fda-to-establish-regulatory-standards-for-antibody-drug-conjugates 2025-07-22T17:24:27+00:00 hourly 0.9 https://trial.medpath.com/news/osteochondral-organoids-emerge-as-breakthrough-platform-for-osteoarthritis-research-and-therapy 2025-07-22T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cooler-heads-raises-11m-series-a-to-expand-fda-cleared-scalp-cooling-system-for-chemotherapy-patients 2025-07-22T15:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/supreme-court-of-canada-to-rule-on-medical-treatment-patent-eligibility-in-landmark-pharmascience-v-janssen-case 2025-07-22T13:23:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-requests-additional-manufacturing-data-for-telix-s-kidney-cancer-diagnostic-drug-zircaix 2025-07-22T13:23:34+00:00 hourly 0.9 https://trial.medpath.com/news/iovance-biotherapeutics-shares-surge-14-on-amtagvi-fda-approval-and-new-ceo-appointment 2025-07-22T13:22:42+00:00 hourly 0.9 https://trial.medpath.com/news/phoremost-unveils-glueseeker-platform-to-accelerate-rational-molecular-glue-drug-discovery 2025-07-22T13:22:10+00:00 hourly 0.9 https://trial.medpath.com/news/eyam-health-and-mmv-partner-to-develop-1-malaria-prevention-shot-using-ai-designed-monoclonal-antibodies 2025-07-22T13:22:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-for-replimune-s-rp1-melanoma-therapy-citing-trial-design-concerns 2025-07-22T13:20:35+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-acquires-vicebio-for-1-15-billion-to-expand-respiratory-vaccine-pipeline-with-molecular-clamp-technology 2025-07-22T13:20:32+00:00 hourly 0.9 https://trial.medpath.com/news/failed-long-covid-drug-trial-reveals-critical-study-design-flaws-as-new-company-plans-restart 2025-07-22T13:19:11+00:00 hourly 0.9 https://trial.medpath.com/news/new-clinical-trials-market-reports-highlight-global-research-landscape-for-vitamin-b12-deficiency-and-hypoglycemia 2025-07-22T13:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/lantheus-completes-789-million-acquisition-of-life-molecular-imaging-gains-fda-approved-alzheimer-s-diagnostic-agent 2025-07-22T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nyxoah-receives-fda-approval-for-genio-neuromodulation-device-to-treat-sleep-apnea 2025-07-22T09:24:05+00:00 hourly 0.9 https://trial.medpath.com/news/daewoong-pharmaceutical-enters-biosimilar-market-with-former-celltrion-executive-leading-new-division 2025-07-22T09:23:43+00:00 hourly 0.9 https://trial.medpath.com/news/zepbound-receives-health-canada-approval-as-first-dual-receptor-obesity-treatment 2025-07-22T09:22:49+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-advances-loxo-435-in-phase-1-forager-1-study-for-fgfr3-altered-advanced-cancers 2025-07-22T05:21:59+00:00 hourly 0.9 https://trial.medpath.com/news/survey-reveals-patient-priorities-in-advanced-colorectal-cancer-treatment-decision-making 2025-07-22T05:21:13+00:00 hourly 0.9 https://trial.medpath.com/news/iovance-biotherapeutics-expands-workforce-with-stock-option-grants-for-new-employees 2025-07-22T02:55:37+00:00 hourly 0.9 https://trial.medpath.com/news/longeveron-licenses-novel-cardiac-stem-cell-technology-to-address-safety-concerns-in-heart-disease-treatment 2025-07-22T01:28:55+00:00 hourly 0.9 https://trial.medpath.com/news/hiv-drugs-show-promise-as-first-prophylactic-treatment-for-htlv-1-virus-in-landmark-australian-study 2025-07-22T01:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/dualitybio-s-her3-targeting-adc-db-1310-receives-fda-fast-track-designation-for-egfr-mutant-lung-cancer 2025-07-22T01:24:52+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-announces-50-billion-us-investment-plan-with-virginia-manufacturing-hub-for-weight-management-and-metabolic-drugs 2025-07-22T01:23:28+00:00 hourly 0.9 https://trial.medpath.com/news/casi-pharmaceuticals-names-david-cory-ceo-to-advance-anti-cd38-antibody-cid-103-program 2025-07-22T01:22:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-takeda-s-hyhub-devices-to-streamline-at-home-hyqvia-immunoglobulin-therapy 2025-07-22T01:22:37+00:00 hourly 0.9 https://trial.medpath.com/news/extended-paxlovid-treatment-reduces-viral-rebound-in-immunocompromised-covid-19-patients 2025-07-21T21:29:04+00:00 hourly 0.9 https://trial.medpath.com/news/livzon-s-dual-target-il-17a-f-antibody-lzm012-outperforms-secukinumab-in-phase-iii-psoriasis-trial 2025-07-21T21:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/covid-19-vaccine-effectiveness-studies-show-waning-protection-over-time-supporting-annual-vaccination 2025-07-21T21:26:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expert-panel-debates-ssri-safety-during-pregnancy-amid-calls-for-stronger-warnings 2025-07-21T21:26:47+00:00 hourly 0.9 https://trial.medpath.com/news/ausperbio-receives-china-cde-clearance-for-phase-iii-trial-of-hepatitis-b-antisense-therapy-ahb-137 2025-07-21T21:26:06+00:00 hourly 0.9 https://trial.medpath.com/news/nestmedic-partners-with-curavit-for-u-s-clinical-trial-of-ai-enabled-prenatal-monitoring-device 2025-07-21T21:25:04+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-study-challenges-decades-of-cholesterol-concerns-about-eggs 2025-07-21T17:36:38+00:00 hourly 0.9 https://trial.medpath.com/news/harmony-trial-introduces-adaptive-parp-inhibitor-strategy-for-metastatic-prostate-cancer-with-focus-on-underrepresented-populations 2025-07-21T17:35:06+00:00 hourly 0.9 https://trial.medpath.com/news/nanogel-armed-car-t-cells-achieve-83-2-tumor-inhibition-rate-in-solid-tumor-model 2025-07-21T17:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/cytomed-therapeutics-advances-novel-car-gamma-delta-t-cell-therapy-to-phase-i-dose-level-2 2025-07-21T17:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/promis-neurosciences-receives-fda-fast-track-designation-for-alzheimer-s-drug-pmn310 2025-07-21T17:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/epirium-bio-completes-first-in-human-trial-of-novel-oral-sarcopenia-treatment-mf-300 2025-07-21T17:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/medgenome-secures-47-5-million-series-e-funding-to-expand-genomic-diagnostics-access-across-india 2025-07-21T17:29:19+00:00 hourly 0.9 https://trial.medpath.com/news/diamedica-therapeutics-secures-30-1-million-to-advance-dm199-for-preeclampsia-and-fetal-growth-restriction 2025-07-21T17:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/lantern-pharma-secures-european-patent-for-ai-developed-cancer-therapy-lp-284 2025-07-21T17:27:48+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-s-orforglipron-shows-promise-as-oral-glp-1-therapy-advances 2025-07-21T17:26:17+00:00 hourly 0.9 https://trial.medpath.com/news/mvp-health-care-partners-with-renalytix-to-expand-access-to-ai-powered-kidney-disease-testing 2025-07-21T17:26:12+00:00 hourly 0.9 https://trial.medpath.com/news/korro-bio-receives-ema-orphan-drug-designation-for-rna-editing-therapy-krro-110-in-alpha-1-antitrypsin-deficiency 2025-07-21T17:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-biopharma-receives-fda-approval-for-groundbreaking-map-targeted-crohn-s-disease-study 2025-07-21T17:24:35+00:00 hourly 0.9 https://trial.medpath.com/news/cerus-corporation-secures-7-2m-dod-contract-amendment-to-advance-trauma-hemorrhage-treatment 2025-07-21T17:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-appoints-biotech-veteran-george-tidmarsh-to-lead-drug-regulation-center-amid-agency-restructuring 2025-07-21T13:33:40+00:00 hourly 0.9 https://trial.medpath.com/news/gecko-inspired-nanoparticles-show-promise-for-targeted-bladder-cancer-therapy 2025-07-21T13:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/ima-group-acquires-medical-research-network-to-expand-cns-clinical-trial-capabilities 2025-07-21T13:29:12+00:00 hourly 0.9 https://trial.medpath.com/news/corteria-pharmaceuticals-advances-first-in-class-crf2-agonists-into-phase-2-heart-failure-and-phase-1-obesity-trials 2025-07-21T13:28:06+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-first-in-class-birch-pollen-immunotherapy-for-severe-hayfever-on-nhs 2025-07-21T13:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/alk-s-tree-pollen-tablet-itulazax-receives-nice-recommendation-for-uk-nhs-reimbursement 2025-07-21T13:27:07+00:00 hourly 0.9 https://trial.medpath.com/news/sab-bio-secures-175-million-funding-to-advance-type-1-diabetes-immunotherapy-through-phase-2b-trial 2025-07-21T13:25:52+00:00 hourly 0.9 https://trial.medpath.com/news/abu-dhabi-investment-authority-invests-200-million-in-indian-medtech-company-meril 2025-07-21T13:25:48+00:00 hourly 0.9 https://trial.medpath.com/news/alkermes-alixorexton-shows-promise-in-phase-2-narcolepsy-trial-achieving-normal-wakefulness-levels 2025-07-21T13:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/omega-funds-closes-oversubscribed-647m-fund-viii-to-accelerate-life-sciences-innovation 2025-07-21T13:25:08+00:00 hourly 0.9 https://trial.medpath.com/news/japanese-researchers-develop-gai-17-novel-stroke-drug-with-six-hour-treatment-window 2025-07-21T13:24:43+00:00 hourly 0.9 https://trial.medpath.com/news/donidalorsen-shows-62-reduction-in-hae-attacks-when-patients-switch-from-other-prophylactics-in-phase-3-study 2025-07-21T13:23:46+00:00 hourly 0.9 https://trial.medpath.com/news/oncozenge-partners-with-meribel-pharma-for-bupizenge-phase-3-manufacturing 2025-07-21T13:23:41+00:00 hourly 0.9 https://trial.medpath.com/news/xvivo-initiates-us-continued-access-protocol-study-for-heart-assist-transport-device-following-successful-preserve-trial 2025-07-21T13:22:07+00:00 hourly 0.9 https://trial.medpath.com/news/brisk-walking-shows-significant-health-benefits-in-large-scale-studies-of-older-adults 2025-07-21T10:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/fda-regulatory-changes-drive-strategic-timing-considerations-and-medical-affairs-team-adaptations 2025-07-21T09:27:50+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-releases-new-sec-guidelines-to-enhance-drug-and-medical-device-approval-process 2025-07-21T09:27:48+00:00 hourly 0.9 https://trial.medpath.com/news/fangzhou-and-novo-nordisk-partner-to-create-ai-powered-chronic-disease-management-ecosystem-in-china 2025-07-21T09:27:40+00:00 hourly 0.9 https://trial.medpath.com/news/ai-repurposed-diabetes-drug-halicin-shows-promise-against-multidrug-resistant-superbugs 2025-07-21T09:27:04+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-s-ilumya-achieves-primary-endpoints-in-two-phase-3-psoriatic-arthritis-trials 2025-07-21T09:26:25+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-acquires-gilgamesh-s-breakthrough-depression-treatment-bretisilocin-for-1-2-billion 2025-07-21T09:26:21+00:00 hourly 0.9 https://trial.medpath.com/news/corestemchemon-partners-with-atg-lifetech-to-advance-organoid-based-preclinical-testing 2025-07-21T09:25:46+00:00 hourly 0.9 https://trial.medpath.com/news/cloudbreak-pharma-s-cbt-004-achieves-primary-endpoint-in-phase-2-trial-for-vascularized-pinguecula 2025-07-21T09:25:04+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-astegolimab-shows-mixed-results-in-copd-trials-phase-iib-study-meets-primary-endpoint 2025-07-21T09:25:01+00:00 hourly 0.9 https://trial.medpath.com/news/venus-remedies-receives-who-gdp-certification-for-advanced-digital-logistics-operations 2025-07-21T09:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-launches-new-glioblastoma-trial-after-patient-shows-complete-tumor-clearance-with-ipilimumab 2025-07-21T09:24:03+00:00 hourly 0.9 https://trial.medpath.com/news/japanese-researchers-begin-human-trials-for-revolutionary-tooth-regeneration-drug 2025-07-21T09:23:36+00:00 hourly 0.9 https://trial.medpath.com/news/protalix-biotherapeutics-appoints-gilad-mamlok-as-new-cfo-to-drive-growth-strategy 2025-07-21T03:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-gut-bacteria-shows-promise-in-phase-1-2a-trial-for-kidney-stone-prevention 2025-07-21T02:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-evobody-bispecific-antibodies-show-promise-in-ovarian-cancer-by-targeting-vg9vd2-t-cells 2025-07-20T21:22:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-panel-overwhelmingly-rejects-otsuka-s-ptsd-drug-combination-in-10-1-vote 2025-07-20T21:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/positive-trial-shows-breastfeeding-safe-for-women-with-hr-positive-breast-cancer-after-treatment-interruption 2025-07-20T21:21:25+00:00 hourly 0.9 https://trial.medpath.com/news/india-develops-indigenous-multi-stage-malaria-vaccine-adfalcivax-targeting-dual-parasite-protection 2025-07-20T17:24:49+00:00 hourly 0.9 https://trial.medpath.com/news/community-pharmacies-emerge-as-key-players-in-pharmacogenetic-testing-implementation 2025-07-20T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-grants-interim-injunction-against-zydus-biosimilar-to-protect-nivolumab-patent-rights 2025-07-20T13:20:44+00:00 hourly 0.9 https://trial.medpath.com/news/oncologists-prescribe-cancer-drugs-23-times-more-after-fda-accelerated-approval-than-traditional-approval 2025-07-20T13:20:42+00:00 hourly 0.9 https://trial.medpath.com/news/turkish-study-links-pfizer-covid-19-vaccine-to-corneal-structural-changes 2025-07-20T09:17:08+00:00 hourly 0.9 https://trial.medpath.com/news/onto-innovation-acquires-semilab-s-materials-analysis-business-for-545-million-to-expand-semiconductor-process-control-portfolio 2025-07-20T01:25:04+00:00 hourly 0.9 https://trial.medpath.com/news/congressional-budget-office-warns-trump-s-proposed-nih-cuts-could-reduce-drug-approvals-by-4-5 2025-07-20T01:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/upc-ruling-protects-generic-drug-development-zentiva-wins-marketing-authorization-case-against-boehringer-ingelheim 2025-07-20T01:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/blinatumomab-achieves-unprecedented-96-97-success-rate-in-pediatric-b-cell-all-treatment 2025-07-20T01:21:05+00:00 hourly 0.9 https://trial.medpath.com/news/b-c-government-reverses-funding-decision-for-rare-disease-treatment-after-expert-committee-resignations 2025-07-19T21:24:44+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-scientists-achieve-first-in-human-in-vivo-car-t-therapy-using-genetically-modified-virus 2025-07-19T21:22:56+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-analysis-reveals-unexpected-safety-signals-for-temozolomide-in-glioma-treatment 2025-07-19T21:22:21+00:00 hourly 0.9 https://trial.medpath.com/news/cochlear-receives-fda-approval-for-world-s-first-smart-cochlear-implant-with-upgradeable-firmware 2025-07-19T21:21:05+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-obesity-accelerates-biological-aging-in-young-adults-study-finds 2025-07-19T21:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/panjab-university-researchers-patent-magnetic-lignin-nano-constructs-for-advanced-3d-cancer-cell-culture 2025-07-19T16:59:10+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-advances-dostarlimab-in-phase-3-colon-cancer-trial-and-phase-2-endometrial-cancer-study 2025-07-19T16:58:08+00:00 hourly 0.9 https://trial.medpath.com/news/tibsovo-listed-on-australian-pbs-offering-first-targeted-therapy-for-rare-bile-duct-cancer 2025-07-19T13:19:53+00:00 hourly 0.9 https://trial.medpath.com/news/cd163-tumor-associated-macrophages-linked-to-improved-nivolumab-outcomes-in-metastatic-renal-cell-carcinoma 2025-07-19T13:19:36+00:00 hourly 0.9 https://trial.medpath.com/news/abivax-phase-3-data-positions-company-for-multi-billion-dollar-market-opportunity 2025-07-19T06:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/champions-oncology-appoints-rob-brainin-as-new-ceo-to-drive-data-platform-expansion 2025-07-19T05:21:42+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-reports-strong-q2-2025-results-with-kisqali-leading-64-growth-surge 2025-07-19T02:55:52+00:00 hourly 0.9 https://trial.medpath.com/news/amphastar-pharmaceuticals-plans-to-quadruple-us-manufacturing-capacity-in-major-domestic-expansion 2025-07-19T01:20:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-osilodrostat-for-second-line-cushing-syndrome-treatment-as-pipeline-advances 2025-07-19T01:20:02+00:00 hourly 0.9 https://trial.medpath.com/news/nanopharmaceutics-completes-phase-ii-enrollment-for-triapine-combination-therapy-in-neuroendocrine-tumors 2025-07-19T01:18:52+00:00 hourly 0.9 https://trial.medpath.com/news/nuwellis-terminates-reverse-hf-clinical-trial-to-refocus-on-outpatient-heart-failure-market 2025-07-18T21:30:32+00:00 hourly 0.9 https://trial.medpath.com/news/australian-researchers-develop-pan-coronavirus-vaccine-candidate-with-99-9-protection-against-multiple-variants 2025-07-18T21:29:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-exzolt-first-oral-treatment-for-northern-fowl-mites-in-poultry 2025-07-18T21:28:51+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-chief-strategy-officer-ryan-richardson-to-step-down-after-seven-year-tenure 2025-07-18T21:28:28+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-guelph-develops-canada-s-first-mrna-bird-flu-vaccine-for-commercial-poultry 2025-07-18T21:26:16+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-wins-appeal-overturns-106-5-million-patent-infringement-verdict-in-heart-valve-case 2025-07-18T21:24:52+00:00 hourly 0.9 https://trial.medpath.com/news/extended-half-life-factor-viii-therapy-reduces-bleeding-episodes-and-injection-frequency-in-hemophilia-a-patients 2025-07-18T21:24:23+00:00 hourly 0.9 https://trial.medpath.com/news/telomir-1-outperforms-standard-chemotherapy-in-reversing-cancer-gene-silencing 2025-07-18T21:22:07+00:00 hourly 0.9 https://trial.medpath.com/news/emerging-dry-eye-therapies-show-promise-blood-serum-drops-and-neuromodulation-lead-innovation-pipeline 2025-07-18T17:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/knight-therapeutics-files-new-drug-submission-for-crexont-in-canada-following-successful-phase-3-trial 2025-07-18T17:28:17+00:00 hourly 0.9 https://trial.medpath.com/news/ojjaara-shows-superior-anemia-control-in-myelofibrosis-achieving-67-transfusion-independence-rate 2025-07-18T17:28:15+00:00 hourly 0.9 https://trial.medpath.com/news/metastasis-directed-radiotherapy-shows-durable-disease-control-in-oligometastatic-renal-cell-carcinoma-without-systemic-therapy 2025-07-18T17:27:34+00:00 hourly 0.9 https://trial.medpath.com/news/lexicon-pharmaceuticals-presents-patient-reported-data-on-diabetic-peripheral-neuropathic-pain-at-aspn-2025 2025-07-18T17:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/belzutifan-demonstrates-superior-quality-adjusted-survival-time-compared-to-everolimus-in-advanced-renal-cell-carcinoma 2025-07-18T17:26:35+00:00 hourly 0.9 https://trial.medpath.com/news/processa-pharmaceuticals-advances-pcs6422-in-phase-2-breast-cancer-trial-with-7-million-funding-boost 2025-07-18T17:26:05+00:00 hourly 0.9 https://trial.medpath.com/news/filgrastim-biosimilars-demonstrate-15-million-cost-savings-potential-in-cancer-care 2025-07-18T17:24:47+00:00 hourly 0.9 https://trial.medpath.com/news/aenova-expands-irish-facility-to-tackle-drug-bioavailability-challenge-with-advanced-spray-drying-technology 2025-07-18T17:24:38+00:00 hourly 0.9 https://trial.medpath.com/news/hengrui-medicine-advances-cancer-pipeline-with-breakthrough-therapy-designations-and-clinical-trial-approvals 2025-07-18T17:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-s-reblozyl-fails-primary-endpoint-in-phase-iii-myelofibrosis-trial-despite-secondary-benefits 2025-07-18T17:23:25+00:00 hourly 0.9 https://trial.medpath.com/news/pediatric-hidradenitis-suppurativa-shows-superior-response-to-adalimumab-over-infliximab-in-real-world-study 2025-07-18T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/telomir-pharmaceuticals-lead-compound-shows-promise-in-reversing-cancer-gene-silencing 2025-07-18T13:23:33+00:00 hourly 0.9 https://trial.medpath.com/news/abvc-biopharma-receives-150k-milestone-payment-advancing-botanical-cns-therapies-through-strategic-partnerships 2025-07-18T13:22:44+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-cancels-mrna-manufacturing-plant-in-japan-amid-declining-vaccine-demand-and-regulatory-uncertainty 2025-07-18T13:21:39+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-florida-researchers-develop-universal-mrna-cancer-vaccine-that-awakens-immune-system 2025-07-18T13:21:37+00:00 hourly 0.9 https://trial.medpath.com/news/german-researchers-develop-gallium-complex-that-triggers-immunogenic-cell-death-to-combat-cancer-metastases 2025-07-18T13:21:02+00:00 hourly 0.9 https://trial.medpath.com/news/btk-inhibitors-challenge-traditional-ms-coverage-models-as-payers-seek-evidence-based-alternatives-to-step-therapy 2025-07-18T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/nuclear-waste-from-manhattan-project-transformed-into-breakthrough-cancer-treatment-at-oak-ridge 2025-07-18T09:15:29+00:00 hourly 0.9 https://trial.medpath.com/news/4dmedical-advances-respiratory-imaging-technology-with-university-partnership-extension-and-ai-development-grant 2025-07-18T09:15:10+00:00 hourly 0.9 https://trial.medpath.com/news/trogenix-strengthens-leadership-team-with-key-clinical-appointments-as-odysseus-platform-advances-toward-clinical-trials 2025-07-18T09:15:08+00:00 hourly 0.9 https://trial.medpath.com/news/deepqure-receives-mfds-approval-for-atrial-fibrillation-trial-of-novel-laparoscopic-renal-denervation-system 2025-07-18T09:14:56+00:00 hourly 0.9 https://trial.medpath.com/news/biomedit-advances-first-in-class-probiotic-antibody-platform-with-18-4m-series-b-funding 2025-07-18T09:14:53+00:00 hourly 0.9 https://trial.medpath.com/news/five-year-pharmacovigilance-study-confirms-safety-of-ntc-s-fixed-dose-eye-drops-for-post-cataract-surgery 2025-07-18T09:14:52+00:00 hourly 0.9 https://trial.medpath.com/news/type-1-diabetes-pipeline-shows-robust-growth-with-85-companies-developing-100-therapeutic-candidates 2025-07-18T05:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-advances-phase-3-study-of-etelcalcetide-for-pediatric-secondary-hyperparathyroidism 2025-07-18T05:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-combinations-transform-advanced-squamous-cell-anal-cancer-treatment-landscape 2025-07-18T03:55:16+00:00 hourly 0.9 https://trial.medpath.com/news/galderma-reports-nine-month-efficacy-data-for-combined-sculptra-and-restylane-treatment-in-glp-1-associated-facial-volume-loss 2025-07-18T01:26:24+00:00 hourly 0.9 https://trial.medpath.com/news/covid-19-boosters-reduce-hospitalization-risk-by-29-in-cancer-patients-large-multi-center-study-shows 2025-07-18T01:22:51+00:00 hourly 0.9 https://trial.medpath.com/news/british-columbia-restricts-sales-of-diabetes-drugs-tirzepatide-and-dulaglutide-to-combat-weight-loss-driven-shortages 2025-07-18T01:22:47+00:00 hourly 0.9 https://trial.medpath.com/news/eledon-pharmaceuticals-to-present-updated-phase-1b-kidney-transplant-data-for-tegoprubart-at-world-transplant-congress-2025 2025-07-18T01:22:09+00:00 hourly 0.9 https://trial.medpath.com/news/neurogen-biomarking-to-present-validation-data-for-at-home-alzheimer-s-blood-biomarker-test-at-aaic-2025 2025-07-18T01:21:36+00:00 hourly 0.9 https://trial.medpath.com/news/avacta-therapeutics-raises-ps3-25-million-and-secures-bond-amendment-to-advance-fap-dox-cancer-therapy 2025-07-18T01:21:30+00:00 hourly 0.9 https://trial.medpath.com/news/canadian-real-world-study-shows-comparable-remission-rates-between-etanercept-biosimilars-and-originator-in-rheumatoid-arthritis 2025-07-18T01:20:36+00:00 hourly 0.9 https://trial.medpath.com/news/nihr-pilots-just-in-time-clinical-trial-initiative-for-pancreatic-cancer-using-pembrolizumab-olaparib-combination 2025-07-18T01:20:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expert-panel-calls-for-revision-of-menopausal-hormone-therapy-warning-labels 2025-07-18T01:19:22+00:00 hourly 0.9 https://trial.medpath.com/news/microbiome-signatures-in-blood-and-gut-emerge-as-promising-biomarkers-for-colorectal-cancer-detection 2025-07-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/acute-ischemic-stroke-pipeline-shows-promise-with-25-therapies-in-development-and-recent-clinical-breakthroughs 2025-07-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/multi-cancer-detection-blood-tests-enter-major-clinical-trial-across-virginia-and-missouri 2025-07-17T21:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisory-panel-rejects-gsk-s-blenrep-combination-therapies-for-multiple-myeloma 2025-07-17T21:24:40+00:00 hourly 0.9 https://trial.medpath.com/news/robotic-assisted-aneurysm-embolization-achieves-94-technical-success-rate-in-six-month-follow-up-study 2025-07-17T21:22:59+00:00 hourly 0.9 https://trial.medpath.com/news/aspect-biosystems-bioprinted-adrenal-tissues-show-promise-for-primary-adrenal-insufficiency-treatment 2025-07-17T21:21:01+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-advances-troriluzole-in-phase-2-3-trial-for-treatment-resistant-ocd-as-pipeline-expands 2025-07-17T21:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-authorizes-juul-e-cigarettes-for-continued-market-sale-after-multiyear-review 2025-07-17T21:20:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-rectal-cancer-drug-metric-fails-to-predict-long-term-survival-tulane-study-finds 2025-07-17T21:20:29+00:00 hourly 0.9 https://trial.medpath.com/news/ambulatory-pharmacists-emerge-as-key-players-in-value-based-care-models-to-address-rising-drug-costs 2025-07-17T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-recalls-bicillin-l-a-due-to-contamination-threatening-syphilis-treatment-amid-rising-congenital-cases 2025-07-17T17:38:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-ends-rare-pediatric-disease-designation-program-after-decade-of-mixed-results 2025-07-17T17:38:18+00:00 hourly 0.9 https://trial.medpath.com/news/citizens-petition-seeks-fda-accelerated-approval-for-nurown-stem-cell-therapy-in-als-based-on-survival-data 2025-07-17T17:35:48+00:00 hourly 0.9 https://trial.medpath.com/news/renovaro-s-engineered-dendritic-cell-therapy-achieves-81-7-tumor-reduction-in-pancreatic-cancer-models 2025-07-17T17:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/nanjing-leads-biolabs-soars-122-on-hong-kong-debut-following-hk-1-1-billion-ipo 2025-07-17T17:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/brazil-s-patent-landscape-transformation-supreme-court-ruling-reshapes-pharmaceutical-ip-strategy 2025-07-17T17:33:07+00:00 hourly 0.9 https://trial.medpath.com/news/one-biosciences-secures-eur15-million-series-a-to-advance-ai-powered-single-cell-cancer-diagnostics-platform 2025-07-17T17:32:13+00:00 hourly 0.9 https://trial.medpath.com/news/keros-therapeutics-initiates-phase-3-renew-trial-for-elritercept-in-myelodysplastic-syndromes-triggers-10m-takeda-milestone 2025-07-17T17:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/seaport-therapeutics-initiates-phase-2b-trial-of-novel-oral-antidepressant-glyphallo 2025-07-17T17:31:48+00:00 hourly 0.9 https://trial.medpath.com/news/moma-therapeutics-initiates-first-in-human-trial-of-werner-helicase-inhibitor-moma-341-for-msi-h-solid-tumors 2025-07-17T17:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/lisata-therapeutics-reports-promising-60-response-rate-in-pancreatic-cancer-trial-with-certepetide 2025-07-17T17:29:13+00:00 hourly 0.9 https://trial.medpath.com/news/harrow-secures-exclusive-us-rights-to-samsung-bioepis-ophthalmology-biosimilars-portfolio 2025-07-17T17:27:56+00:00 hourly 0.9 https://trial.medpath.com/news/i-mab-acquires-bridge-health-biotech-to-strengthen-givastomig-bispecific-antibody-development 2025-07-17T17:27:53+00:00 hourly 0.9 https://trial.medpath.com/news/regen-biopharma-prepares-phase-i-trial-for-hemaxellerate-stem-cell-therapy-targeting-severe-aplastic-anemia 2025-07-17T17:27:10+00:00 hourly 0.9 https://trial.medpath.com/news/diamedica-s-dm199-shows-promising-blood-pressure-reduction-in-phase-2-preeclampsia-trial 2025-07-17T17:27:08+00:00 hourly 0.9 https://trial.medpath.com/news/cube-biotech-appoints-michael-bencak-as-new-ceo-to-drive-global-expansion-in-protein-technologies 2025-07-17T17:26:59+00:00 hourly 0.9 https://trial.medpath.com/news/uromems-receives-fda-and-ansm-clearance-for-pivotal-trial-of-smart-artificial-urinary-sphincter 2025-07-17T17:26:12+00:00 hourly 0.9 https://trial.medpath.com/news/fifty1-labs-partners-with-biospark-ai-to-accelerate-drug-repurposing-through-advanced-literature-mining 2025-07-17T17:25:35+00:00 hourly 0.9 https://trial.medpath.com/news/moleculin-appoints-roche-veteran-adriano-treve-as-strategic-advisor-ahead-of-phase-3-aml-trial-data 2025-07-17T17:24:27+00:00 hourly 0.9 https://trial.medpath.com/news/vor-bio-appoints-telitacicept-development-expert-dr-qing-zuraw-as-chief-development-officer 2025-07-17T17:24:25+00:00 hourly 0.9 https://trial.medpath.com/news/congressional-lawmakers-push-for-fast-track-approval-of-antiparasitic-treatments-as-new-world-screwworm-threat-approaches-u-s-border 2025-07-17T17:24:23+00:00 hourly 0.9 https://trial.medpath.com/news/saluda-medical-launches-eva-sensing-technology-for-personalized-spinal-cord-stimulation-in-u-s 2025-07-17T17:23:59+00:00 hourly 0.9 https://trial.medpath.com/news/trivarx-advances-ai-powered-depression-screening-with-veterans-affairs-clinical-trial 2025-07-17T17:23:47+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-and-pfizer-launch-direct-to-patient-eliquis-program-with-40-price-discount 2025-07-17T17:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/velocity-clinical-research-partners-with-palantir-to-automate-clinical-trial-payment-reconciliation-using-ai 2025-07-17T17:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/10x-genomics-partners-with-singapore-institute-to-launch-ai-driven-cancer-drug-discovery-study 2025-07-17T17:22:59+00:00 hourly 0.9 https://trial.medpath.com/news/ginkgo-bioworks-launches-automated-adme-profiling-service-to-accelerate-small-molecule-drug-discovery 2025-07-17T17:22:46+00:00 hourly 0.9 https://trial.medpath.com/news/organoid-technology-advances-diabetes-research-with-sophisticated-3d-models-and-therapeutic-applications 2025-07-17T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bedtime-blood-pressure-medication-dosing-shows-superior-nighttime-control-in-chinese-trial 2025-07-17T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ema-grants-orphan-drug-designations-for-fragile-x-syndrome-and-radiation-induced-maculopathy-treatments 2025-07-17T14:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/bird-foundation-approves-additional-funding-for-itol-102-type-1-diabetes-cell-therapy-following-fda-pre-ind-meeting 2025-07-17T13:29:47+00:00 hourly 0.9 https://trial.medpath.com/news/jaya-biosciences-secures-key-asian-patents-for-novel-alzheimer-s-gene-therapy-targeting-lysosomal-enzyme-defects 2025-07-17T13:29:36+00:00 hourly 0.9 https://trial.medpath.com/news/european-court-cancels-biogen-s-extended-market-exclusivity-for-multiple-sclerosis-drug-tecfidera 2025-07-17T13:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/hansa-biopharma-secures-24-3m-funding-as-idefirix-sales-surge-76-in-q2-2025 2025-07-17T13:27:59+00:00 hourly 0.9 https://trial.medpath.com/news/mmj-international-ceo-alleges-dea-obstruction-of-fda-authorized-cannabis-research-for-neurological-diseases 2025-07-17T13:27:50+00:00 hourly 0.9 https://trial.medpath.com/news/newer-antiseizure-medications-show-improved-safety-profile-during-pregnancy 2025-07-17T10:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/nanochon-receives-health-canada-approval-for-first-in-human-trial-of-3d-printed-knee-cartilage-implant 2025-07-17T09:25:20+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-proves-safe-and-effective-for-octogenarians-with-b-cell-lymphoma 2025-07-17T09:21:09+00:00 hourly 0.9 https://trial.medpath.com/news/cosmo-pharmaceuticals-launches-first-in-class-acne-treatment-winlevi-in-southeast-asia 2025-07-17T09:19:05+00:00 hourly 0.9 https://trial.medpath.com/news/sarepta-therapeutics-implements-400-million-cost-cutting-plan-amid-regulatory-challenges-for-gene-therapy 2025-07-17T05:25:21+00:00 hourly 0.9 https://trial.medpath.com/news/ihc-testing-enables-rapid-tp53-mutation-detection-in-mds-and-aml-patients 2025-07-17T05:18:39+00:00 hourly 0.9 https://trial.medpath.com/news/aav-gene-therapy-pipeline-expands-with-180-companies-developing-250-treatments-despite-recent-setbacks 2025-07-17T03:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/pharma-industry-adapts-strategic-drug-development-amid-funding-crisis-and-regulatory-uncertainty 2025-07-17T02:57:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-implements-major-workforce-reduction-and-policy-changes-amid-regulatory-overhaul 2025-07-17T02:56:36+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-strengthens-neuroscience-portfolio-with-14-6-billion-intra-cellular-acquisition 2025-07-17T01:21:57+00:00 hourly 0.9 https://trial.medpath.com/news/openevidence-raises-210-million-series-b-to-expand-ai-powered-medical-research-platform-for-physicians 2025-07-17T01:21:45+00:00 hourly 0.9 https://trial.medpath.com/news/yale-researchers-engineer-novel-antibody-rna-therapy-platform-for-treatment-resistant-cancers 2025-07-17T01:20:33+00:00 hourly 0.9 https://trial.medpath.com/news/eight-healthy-babies-born-in-britain-using-three-person-dna-technique-to-prevent-mitochondrial-disease 2025-07-17T01:19:24+00:00 hourly 0.9 https://trial.medpath.com/news/csir-launches-nationwide-phenome-india-health-cohort-study-to-develop-personalized-disease-risk-predictions 2025-07-17T01:18:55+00:00 hourly 0.9 https://trial.medpath.com/news/22nd-century-group-expands-vln-reduced-nicotine-cigarette-partnerships-ahead-of-fda-mandate 2025-07-17T01:18:01+00:00 hourly 0.9 https://trial.medpath.com/news/overture-orthopaedics-launches-overtureti-knee-resurfacing-system-for-early-osteoarthritis-treatment 2025-07-17T01:17:18+00:00 hourly 0.9 https://trial.medpath.com/news/idt-launches-hdr-enhancer-protein-to-boost-crispr-gene-editing-efficiency-in-therapeutic-applications 2025-07-17T01:16:41+00:00 hourly 0.9 https://trial.medpath.com/news/nexgel-expands-stada-partnership-with-1-million-investment-for-digestive-enzyme-and-scar-treatment-products 2025-07-17T01:16:29+00:00 hourly 0.9 https://trial.medpath.com/news/cms-proposes-new-payment-structure-for-skin-substitutes-regenerative-medicine-companies-welcome-reform 2025-07-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dogs-demonstrate-high-accuracy-in-detecting-parkinson-s-disease-through-scent-analysis 2025-07-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/wehi-partners-with-parkinson-s-research-foundation-to-accelerate-drug-discovery-for-world-s-fastest-growing-neurological-condition 2025-07-16T23:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/endtb-q-trial-reveals-need-for-personalized-treatment-in-drug-resistant-tuberculosis 2025-07-16T21:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/cepi-awards-5-million-to-nagasaki-university-for-ai-powered-nanoball-mrna-vaccine-platform-against-disease-x 2025-07-16T21:31:03+00:00 hourly 0.9 https://trial.medpath.com/news/neocast-liquid-embolic-shows-promise-for-pain-free-treatment-of-chronic-subdural-hematoma 2025-07-16T21:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-invalidates-shockwave-medical-s-intravascular-lithotripsy-patent-in-precedential-ruling 2025-07-16T21:28:49+00:00 hourly 0.9 https://trial.medpath.com/news/okyo-pharma-secures-1-9m-non-dilutive-funding-following-positive-phase-2-results-and-fda-fast-track-designation 2025-07-16T21:25:40+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-partners-with-cspc-for-ai-driven-drug-discovery-platform-to-develop-novel-oral-therapies 2025-07-16T21:25:26+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-and-intellia-advance-crispr-gene-therapy-trial-for-hemophilia-b-treatment 2025-07-16T21:25:06+00:00 hourly 0.9 https://trial.medpath.com/news/quetzal-therapeutics-launches-with-50-million-to-advance-oral-arsenic-trioxide-therapy-for-acute-promyelocytic-leukemia 2025-07-16T21:24:55+00:00 hourly 0.9 https://trial.medpath.com/news/msbai-secures-2m-dod-phase-iii-contract-for-guru-generation-2-ai-platform 2025-07-16T21:22:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-reviewers-flag-discordant-results-for-rexulti-sertraline-ptsd-treatment-ahead-of-advisory-committee-meeting 2025-07-16T21:22:05+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-acquires-sanofi-s-new-jersey-manufacturing-site-to-expand-u-s-sterile-drug-production 2025-07-16T17:34:17+00:00 hourly 0.9 https://trial.medpath.com/news/polypid-unveils-60-day-glp-1-delivery-platform-to-transform-diabetes-and-weight-management-treatment 2025-07-16T17:34:10+00:00 hourly 0.9 https://trial.medpath.com/news/qualigen-therapeutics-secures-global-patent-protection-for-cancer-drug-qn-302-across-25-countries 2025-07-16T17:29:57+00:00 hourly 0.9 https://trial.medpath.com/news/miplyffa-shows-5-year-sustained-efficacy-in-rare-npc-disease-extension-study 2025-07-16T17:29:52+00:00 hourly 0.9 https://trial.medpath.com/news/voyager-therapeutics-advances-novel-apoe4-gene-therapy-for-alzheimer-s-disease-using-iv-delivered-tracer-platform 2025-07-16T17:28:49+00:00 hourly 0.9 https://trial.medpath.com/news/cystic-fibrosis-foundation-commits-additional-24-million-to-prime-medicine-for-gene-editing-therapy-development 2025-07-16T17:28:43+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-leap-receives-fda-ind-clearance-for-first-in-class-oral-il-2-modulator-gl-il2-138 2025-07-16T17:28:41+00:00 hourly 0.9 https://trial.medpath.com/news/cue-101-combination-therapy-achieves-50-response-rate-in-hpv-head-and-neck-cancer-trial 2025-07-16T17:27:49+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-raises-2025-outlook-as-oncology-portfolio-drives-24-growth 2025-07-16T17:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-reviewers-question-efficacy-of-otsuka-s-brexpiprazole-zoloft-combination-for-ptsd-treatment 2025-07-16T17:27:04+00:00 hourly 0.9 https://trial.medpath.com/news/endeavor-biomedicines-receives-dual-orphan-drug-designation-for-taladegib-in-idiopathic-pulmonary-fibrosis 2025-07-16T17:26:28+00:00 hourly 0.9 https://trial.medpath.com/news/logicare3pl-secures-exclusive-distribution-partnership-for-chirhostim-diagnostic-product 2025-07-16T17:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/stargardt-disease-pipeline-shows-promising-progress-with-multiple-gene-therapies-advancing-to-late-stage-trials 2025-07-16T17:26:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-biosimilar-application-for-bat2506-proposed-golimumab-alternative 2025-07-16T17:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/sandboxaq-and-ioncologi-partner-to-develop-ai-driven-mrna-vaccine-for-glioblastoma 2025-07-16T17:26:03+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-ai-receives-fda-510-k-clearance-for-ecg-low-ef-software-to-detect-heart-failure-risk 2025-07-16T17:25:44+00:00 hourly 0.9 https://trial.medpath.com/news/piccolo-medical-receives-fda-clearance-for-next-generation-smartpicc-technology 2025-07-16T17:25:08+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-cincinnati-launches-phase-2-trial-of-novel-endocannabinoid-enhancing-drug-for-multiple-sclerosis-spasticity 2025-07-16T17:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-initiates-pele-clinical-trial-for-onyx-liquid-embolic-system-in-peripheral-arterial-hemorrhage 2025-07-16T17:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/msc-derived-extracellular-vesicles-show-promise-as-cell-free-therapeutics-across-multiple-disease-areas 2025-07-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cms-launches-multi-state-payment-model-to-expand-access-to-sickle-cell-gene-therapies 2025-07-16T13:29:10+00:00 hourly 0.9 https://trial.medpath.com/news/sprim-pro-and-obviohealth-expand-partnership-to-accelerate-digital-clinical-trial-innovation 2025-07-16T13:28:15+00:00 hourly 0.9 https://trial.medpath.com/news/ibi343-shows-promising-efficacy-in-cldn18-2-positive-gastric-cancer-with-improved-safety-profile 2025-07-16T13:26:30+00:00 hourly 0.9 https://trial.medpath.com/news/australian-companies-form-strategic-alliance-to-boost-advanced-therapy-manufacturing-capacity 2025-07-16T13:26:16+00:00 hourly 0.9 https://trial.medpath.com/news/uk-digital-health-platform-numan-raises-60m-to-expand-into-women-s-health 2025-07-16T13:26:14+00:00 hourly 0.9 https://trial.medpath.com/news/atricure-completes-enrollment-in-landmark-6500-patient-leaaps-trial-for-stroke-prevention 2025-07-16T13:25:45+00:00 hourly 0.9 https://trial.medpath.com/news/sino-biopharm-acquires-lanova-medicines-for-950m-expanding-innovative-drug-pipeline 2025-07-16T13:25:43+00:00 hourly 0.9 https://trial.medpath.com/news/stelara-biosimilars-capture-market-share-as-j-j-s-blockbuster-drug-faces-33-7-sales-decline 2025-07-16T13:25:08+00:00 hourly 0.9 https://trial.medpath.com/news/ps17-9-million-wellcome-grant-funds-major-initiative-to-combat-deadly-fungal-infections 2025-07-16T13:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/apple-airpods-pro-2-receive-fda-clearance-as-over-the-counter-hearing-aids 2025-07-16T13:22:19+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-sar446597-gene-therapy-receives-fda-fast-track-designation-for-geographic-atrophy-treatment 2025-07-16T13:22:17+00:00 hourly 0.9 https://trial.medpath.com/news/icon-leads-phase-1-clinical-trial-performance-with-highest-sponsor-satisfaction-score 2025-07-16T13:21:42+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-diabetic-retinopathy-screening-achieves-99-accuracy-and-expands-to-pharmacy-networks 2025-07-16T10:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/nci-initiates-4-8-million-clinical-trial-of-senhwa-s-first-in-class-cancer-drug-cx-5461 2025-07-16T09:16:49+00:00 hourly 0.9 https://trial.medpath.com/news/4moving-biotech-initiates-phase-2a-trial-of-first-in-class-glp-1-therapy-for-knee-osteoarthritis 2025-07-16T09:16:40+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-anselamimab-fails-primary-endpoint-in-phase-iii-al-amyloidosis-trial-shows-promise-in-patient-subgroup 2025-07-16T09:15:17+00:00 hourly 0.9 https://trial.medpath.com/news/phase-scientific-secures-exclusive-u-s-distribution-rights-for-febridx-rapid-respiratory-infection-test 2025-07-16T09:15:08+00:00 hourly 0.9 https://trial.medpath.com/news/pragmatic-clinical-trials-bridge-gap-between-research-and-real-world-healthcare-practice 2025-07-16T05:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/mcmaster-study-identifies-most-effective-treatments-for-chronic-hives-through-comprehensive-meta-analysis 2025-07-16T05:27:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-letters-to-seven-companies-marketing-illegal-opioid-alternative-products-containing-7-hydroxymitragynine 2025-07-16T05:22:54+00:00 hourly 0.9 https://trial.medpath.com/news/who-includes-arkbio-s-ziresovir-in-pediatric-rsv-drug-priority-list-marking-first-chinese-anti-rsv-drug-recognition 2025-07-16T05:21:37+00:00 hourly 0.9 https://trial.medpath.com/news/btx-a51-shows-promise-in-relapsed-refractory-aml-with-notable-activity-in-runx1-mutated-patients 2025-07-16T05:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/expert-calls-for-standardized-reflexive-biomarker-testing-to-address-treatment-delays-in-lung-cancer 2025-07-16T02:55:55+00:00 hourly 0.9 https://trial.medpath.com/news/immorta-bio-advances-senolytic-immunotherapy-senovax-toward-phase-i-iia-trial-in-advanced-nsclc 2025-07-16T01:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/aptar-pharma-acquires-mod3-pharma-s-clinical-trial-manufacturing-capabilities-to-strengthen-early-phase-drug-development-services 2025-07-16T01:19:53+00:00 hourly 0.9 https://trial.medpath.com/news/repare-therapeutics-licenses-pkmyt1-inhibitor-lunresertib-to-debiopharm-in-267m-deal 2025-07-16T01:19:49+00:00 hourly 0.9